<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMJ Open</journal-id><journal-id journal-id-type="iso-abbrev">BMJ Open</journal-id><journal-id journal-id-type="hwp">bmjopen</journal-id><journal-id journal-id-type="publisher-id">bmjopen</journal-id><journal-title-group><journal-title>BMJ Open</journal-title></journal-title-group><issn pub-type="epub">2044-6055</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name><publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23166120</article-id><article-id pub-id-type="pmc">3533117</article-id><article-id pub-id-type="publisher-id">bmjopen-2012-001079</article-id><article-id pub-id-type="doi">10.1136/bmjopen-2012-001079</article-id><article-categories><subj-group subj-group-type="heading"><subject>Complementary Medicine</subject><subj-group><subject>Research</subject></subj-group></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>1506</subject><subject>1685</subject><subject>1727</subject><subject>1714</subject><subject>1723</subject></subj-group></article-categories><title-group><article-title>A preliminary prospective study of nutritional, psychological and combined therapies for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in a private care setting</article-title><alt-title alt-title-type="short">Preliminary prospective study for the treatment of ME/CFS</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Arroll</surname><given-names>Megan Anne</given-names></name></contrib><contrib contrib-type="author"><name><surname>Howard</surname><given-names>Alex</given-names></name></contrib></contrib-group><aff>Department of Research, The Optimum Health Clinic, London, UK</aff><author-notes><corresp><label>Correspondence to</label> Dr Megan Arroll; <email>drarroll@theoptimumhealthclinic.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>19</day><month>11</month><year>2012</year></pub-date><volume>2</volume><issue>6</issue><elocation-id>e001079</elocation-id><history><date date-type="received"><day>27</day><month>2</month><year>2012</year></date><date date-type="accepted"><day>15</day><month>10</month><year>2012</year></date></history><permissions><copyright-statement>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</copyright-statement><copyright-year>2012</copyright-year><license license-type="open-access"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/">http://creativecommons.org/licenses/by-nc/2.0/</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/legalcode">http://creativecommons.org/licenses/by-nc/2.0/legalcode</ext-link>.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="bmjopen-2012-001079.pdf"/><self-uri content-type="draft-revisions-pdf" xlink:type="simple" xlink:href="bmjopen-2012-001079.draft_revisions.pdf"/><self-uri content-type="reviewers-comments-pdf" xlink:type="simple" xlink:href="bmjopen-2012-001079.reviewer_comments.pdf"/><abstract><sec><title>Background</title><p>Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a condition characterised by severe and persistent fatigue, neurological disturbances, autonomic and endocrine dysfunctions and sleep difficulties that have a pronounced and significant impact on individuals&#x02019; lives. Current National Institute for Health and Clinical Excellence guidelines within the UK suggest that this condition should be treated with cognitive behavioural therapy and/or graded exercise therapy, where appropriate. There is currently a lack of an evidence base concerning alternative techniques that may be beneficial to those with ME/CFS.</p></sec><sec><title>Objectives</title><p>This study aimed to investigate whether three modalities of psychology, nutrition and combined treatment influenced symptom report measures in those with ME/CFS over a 3-month time period and whether there were significant differences in these changes between groups.</p></sec><sec><title>Design and setting</title><p>This is a preliminary prospective study with one follow-up point conducted at a private secondary healthcare facility in London, UK.</p></sec><sec><title>Participants</title><p>138 individuals (110 females, 79.7%; 42 participants in psychology, 44 in nutrition and 52 in combined) participated at baseline and 72 participants completed the battery of measures at follow-up (52.17% response rate; 14, 27 and 31 participants in each group, respectively).</p></sec><sec><title>Outcome measures</title><p>Self-reported measures of ME/CFS symptoms, functional ability, multidimensional fatigue and perceived control.</p></sec><sec><title>Results</title><p>Baseline comparisons showed those in the combined group had higher levels of fatigue. At follow-up, all groups saw improvements in fatigue, functional ability and symptomatology; those within the psychology group also experienced a shift in perceived control over time.</p></sec><sec><title>Conclusions</title><p>This study provides early evidence that psychological, nutritional and combined techniques for the treatment of ME/CFS may influence symptomatology, fatigue, function and perceived control. However, these results must be viewed with caution as the allocation to groups was not randomised, there was no control group and the study suffered from high drop-out rates.</p></sec></abstract><kwd-group><kwd>Complementary Medicine</kwd><kwd>Social Medicine</kwd><kwd>Rehabilitation Medicine</kwd></kwd-group></article-meta></front><body><boxed-text position="float"><caption><title>Article summary</title></caption><sec><title>Article focus</title><list list-type="bullet"><list-item><p>This preliminary prospective study investigated three (psychological, nutritional and combined) tailored interventions for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) over time.</p></list-item><list-item><p>Differences between the reported changes over time between groups were also assessed.</p></list-item></list></sec><sec><title>Key messages</title><list list-type="bullet"><list-item><p>Psychological, nutritional and combined approaches for the management of ME/CFS influenced symptomatology over time in some individuals with this disorder.</p></list-item><list-item><p>Self-reported functional ability (physical and social) are influenced following tailored interventions lasting 3&#x02005;months.</p></list-item><list-item><p>This study provides preliminary evidence that tailored psychological, nutritional and combined interventions may influence self-reported symptomatology in some people with ME/CFS; however, due to the study's methodological limitations, it is important that these findings are investigated further in high-quality randomised controlled studies.</p></list-item></list></sec><sec><title>Strengths and limitations of this study</title><list list-type="bullet"><list-item><p>The findings here are an initial step to fill the gap in the extant literature regarding the utility of tailored and multidisciplinary (psychological, nutritional and combined) treatments for ME/CFS.</p></list-item><list-item><p>There is bias in this study as the participants were self-selected in the sense that they chose to attend the clinic and which treatment option they preferred (with advice), that is, the study was not randomised.</p></list-item><list-item><p>There were low retention rates in this study which may constitute a bias in that those who remained in the study may have experienced benefits and those who experienced little or no benefits may have dropped out.</p></list-item></list></sec></boxed-text><sec id="s1"><title>Introduction</title><p>Myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS) is a condition characterised by a prolonged and debilitating fatigue, although the exact cause of this disorder is still under debate. Owing to the lack of a definitive biological marker, diagnosis is made on the basis of the exclusion of other explanatory conditions. The most widely used case definition by the Centers for Disease Control (CDC)<xref ref-type="bibr" rid="R1">1</xref> states that there must be at least 6&#x02005;months severe fatigue of a new and definite onset, not the result of an ongoing exertion, not alleviated by rest and resulting in reduced levels of physical activity. The CDC definition also sets out a series of minor complaints that must accompany the fatigue (cognitive impairment, sore throat, tender cervical or axillary lymph nodes, muscle pain, multijoint pain, headaches of a new type, pattern or severity at onset, unrefreshing sleep and postexertion malaise), with individuals needing to have the occurrence of four or more symptoms to be diagnosed with ME/CFS. Estimates of the prevalence of ME/CFS have been made as low as 3 and as high as 2800/100&#x02005;000.<xref ref-type="bibr" rid="R2">2</xref></p><p>The most widely researched strategies for alleviating the symptoms of ME/CFS are the cognitive behaviour therapy (CBT) and graded exercise therapy (GET). Two reviews of studies on CBT<xref ref-type="bibr" rid="R3">3</xref>
<xref ref-type="bibr" rid="R4">4</xref> found that it significantly improved physical functioning in adult outpatients as compared with medical management, counselling, guided support, education and support or relaxation. Regarding GET, a systematic review illustrated that this form of therapy was potentially beneficial for people with ME/CFS, especially when combined with a patient education programme.<xref ref-type="bibr" rid="R5">5</xref> However, drop-out rates were higher in the GET groups than control groups suggesting that individuals with ME/CFS are averse to this type of therapy. Recently, a large-scale, longitudinal study investigating the CBT, GET, adaptive pacing therapy (APT) and specialist medical care (SMC) which had very low drop-out rates, found that CBT and GET (when added to SMC) were moderately effective outpatient treatments for this patient group as opposed to APT or SMC alone.<xref ref-type="bibr" rid="R6">6</xref></p><p>Although CBT and GET studies have shown some promising outcomes, there is no known cure for ME/CFS. Therefore the National Institute for Health and Clinical Excellence (NICE)<xref ref-type="bibr" rid="R7">7</xref> recommends a number of symptom management strategies and interventions aimed at helping individuals to cope with their condition and reduce physical deconditioning brought about by the illness. Pharmacological interventions are, at times, suggested for patients with poor sleep or pain, for instance, low-dose antidepressants, as these have been shown to be effective.<xref ref-type="bibr" rid="R8 R9 R10 R11 R12 R13 R14">8&#x02013;14</xref> However, patient expectations must be realistic as the drugs may help elevate mood and psychological outlook, but not reduce fatigue and other symptomatology associated with ME/CFS.<xref ref-type="bibr" rid="R15">15</xref> Numerous drugs such as thyroxin, hydrocortisone and antiviral agents are not advised by NICE due to contradictory findings.<xref ref-type="bibr" rid="R16">16</xref>
<xref ref-type="bibr" rid="R17">17</xref></p><p>In terms of function and quality-of-life management, NICE offers general advice concerning sleep management, appropriate rest periods and pacing. Sleep hygiene instruction, together with pharmacological treatment tailored to the individual patient, can be beneficial in combating fatigue.<xref ref-type="bibr" rid="R18">18</xref> Dietary management may also reduce symptomatology for those with concurrent irritable bowel syndrome,<xref ref-type="bibr" rid="R19">19</xref> although this is not currently recommended by NICE. Dietary supplementation has been investigated in relation to ME/CFS. Fatty acids,<xref ref-type="bibr" rid="R20">20</xref> folic acid,<xref ref-type="bibr" rid="R21">21</xref> vitamin C,<xref ref-type="bibr" rid="R22">22</xref> co-enzyme Q10,<xref ref-type="bibr" rid="R23">23</xref> magnesium,<xref ref-type="bibr" rid="R24">24</xref> multivitamins<xref ref-type="bibr" rid="R25">25</xref> and minerals<xref ref-type="bibr" rid="R26">26</xref> have all been shown to reduce symptomatology in ME/CFS patients. However, other studies have shown conflicting findings with regard to nutritional supplementation, therefore it is perhaps wise to treat with supplements on a case-by-case basis.<xref ref-type="bibr" rid="R27">27</xref>
<xref ref-type="bibr" rid="R28">28</xref></p><p>Owing to the lack of clear and definitive treatment strategies, individuals often seek out complementary and alternative medicines (CAM). Although NICE does not recommend the use of CAM they do acknowledge that many people with ME/CFS use such therapies and find them beneficial for symptom management. This view is due to the lack of published evidence for the effectiveness of these treatments. Examples of CAM treatments used by individuals with ME/CFS include religious healing, massage therapy, relaxation, meditation, homoeopathy, acupuncture, naturopathy and herbal therapies;<xref ref-type="bibr" rid="R29">29</xref>
<xref ref-type="bibr" rid="R30">30</xref> patient satisfaction with such approaches as CAM has been high, over 80% in some instances.<xref ref-type="bibr" rid="R29">29</xref> A recent systematic review of such interventions identified 70 controlled clinical trials (randomised and non-randomised) and found that 86% of these studies illustrated at least one positive effect, with 74% showing a decrease in illness-related symptomatology.<xref ref-type="bibr" rid="R31">31</xref> Meditative or mindfulness approaches warranted further investigation based on these results as did supplement programmes of magnesium, <sc>l</sc>-carnitine and <italic>S</italic>-adenosylmethionine. A subsequent review based solely on randomised controlled trials (RCTs) of CAM techniques identified 26 such studies and observed that qigong, massage and tuina (approaches based within the Chinese traditional medicine and based upon relaxation and connection with the body) illustrated positive effects as did supplementation studies utilising nicotinamide adenine dinucleotide and magnesium.<xref ref-type="bibr" rid="R32">32</xref> However, within both reviews it was noted that the methodological quality of reporting was poor and the sample sizes in these studies were small; hence ability to draw strong conclusions on the efficacy of CAM methods is limited. Porter <italic>et al</italic><xref ref-type="bibr" rid="R31">31</xref> did note that individualised treatment protocols which include a range of tailored strategies are a promising area for further investigation for this complex, multisystem illness.</p><sec id="s1a"><title>Objectives</title><p>There is still much debate and uncertainty regarding alternative interventions for those with ME/CFS. A recent review of CAM techniques<xref ref-type="bibr" rid="R31">31</xref> highlight the need for further exploration of individually tailored interventions for the alleviation of the condition's often debilitating and an intrusive symptomatology. This study therefore aims to provide preliminary evidence for the utility of three types of approaches (psychological, nutritional and combined) to the management of ME/CFS over time (baseline and follow-up) offered at a private healthcare centre in the UK.</p></sec></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Study design and setting</title><p>This preliminary prospective study aimed to investigate whether psychological, nutritional and combined approaches to the treatment of ME/CFS influenced symptom report measures over a 3-month time period and whether there were significant differences in these changes among groups. The research was conducted at a private secondary healthcare facility. All potential patients of the clinic were first asked to complete a comprehensive symptom profile and medical history, including questions relating to triggering factors, psychology subtypes and structural/biological subtypes (this is distinct from the research data collected). Subsequent to this, every individual received a 15&#x02005;min screening with one of the practitioners (please note, this was neither of the authors of the current study) who recommended the best course of action for his/her needs; ie, the psychology-related intervention, nutritional advice and support or a combination of the two.</p><p>All individuals requesting treatment at the private care setting were offered the opportunity to participate in the study. Those who expressed an interest (N=145) were emailed a spreadsheet that contained the questionnaires and asked to complete it at their convenience. Informed consent was obtained prior to the completion of the questionnaires and the study was approved by the University of East London Ethics Committee. Participants were told that they could withdraw from the study at any time and that withdrawal would not affect their care at the clinic. Participants were allowed to ask questions at any point during the study and no deception was used as the participants were informed of the nature of the research programme before they agreed to participate. Subsequently, participants were requested to complete the questionnaire pack on a second occasion, 3&#x02005;months from the baseline measures.</p><sec id="s2a1"><title>Psychology</title><p>The clinic offers a 3-month intervention which consists of a combination of neuro-linguistic programming (NLP), emotional freedom technique (EFT), life coaching and hypnotherapy/self-hypnosis constructed in a manner specific to the needs of those with ME/CFS. The primary aim of this approach is to reduce the anxiety that is associated with having a debilitating and unpredictable condition, improve emotional well-being and help individuals slowly manage and increase their activity within their own limits (ie, pacing). The programme is offered as a series of group sessions and the peer support is seen as an important component of the intervention, which is solidified via the use of moderated online support forums, narratives of previous clients&#x02019; experiences and online materials that can be accessed as often as necessary. In addition to, or as an alternative to this course, individuals receive a series of one-to-one sessions and for the most severely affected ME/CFS patients, telephone sessions are arranged and support materials can be accessed in their own homes.</p><p>Over the 3-month period of this preliminary study, the participants experienced one of three treatment options. The first option included 13&#x02005;h of practitioner contact time in a mix of group training in person, group telephone conference calls and one-to-one telephone sessions, the second option was 4&#x02005;h of one-to-one telephone sessions and the final option was 3&#x02005;h of in-person sessions. All participants had access to various support materials which included CDs and online resources. The amount of time spent on these was patient-led, but was in the region of a further 6&#x02005;h. All the practitioners offering this option are qualified in hypnotherapy, NLP, life coaching and EFT and undergo an intensive period of training in the clinic's own integrative approach (please see Howard and Arroll<xref ref-type="bibr" rid="R33">33</xref> for more details of this approach) and ongoing supervision (individual and group supervision on a biweekly basis) from the department director, who is the only senior practitioner in the team.</p></sec><sec id="s2a2"><title>Nutrition</title><p>Tailored nutritional therapy is achieved via one-to-one consultations with individuals. To begin, a very detailed history is taken based upon the information given in the aforementioned symptom profile. Qualified nutritional therapists (who have been given specialist training regarding ME/CFS from the clinic) then suggest tests consistent with symptomatology, for instance the Adrenal Stress Index Test, comprehensive stool analysis/gastrointestinal function, vitamin and mineral status, etc. Results from these tests are then used to compose an evidence-driven diet and supplement programme. As most cases of ME/CFS are complex involving multiple body systems, this process is often iterative and follow-up consultations are necessary to check progress and make alterations to the protocol. The nutritional therapy programme consists of an initial 1&#x02005;h evaluation (which includes the tailored advice) and a follow-up approximately every 6&#x02005;weeks; therefore, during the course of the present study, the participants received a minimum of two 1&#x02005;h sessions with email support for any queries and detailed nutritional guidance. All the nutritional therapists are qualified to the diploma level and members of (voluntary) regulatory bodies such as the British Association for Applied Nutrition and Nutritional Therapy and the Complementary and Natural Healthcare Council. Similar to the psychology department, the nutrition department is led by one senior practitioner who supervises the team with individual and group supervisory arrangements.</p></sec><sec id="s2a3"><title>Combined</title><p>Within the combined programme, a multidisciplinary approach is taken with practitioners discussing the patients in case meetings to ensure that the psychological and nutritional aspects complement each other to achieve the best outcome. It should be noted that the interventions in the combined programme are phased-in as it was found that asking individuals to engage in numerous therapeutic activities at the same time resulted in high drop-out rates.</p></sec></sec><sec id="s2b"><title>Primary outcome measures</title><sec id="s2b1"><title>Medical Outcomes Survey Short-Form 36 (SF-36)</title><p>This 36-item measure is the short form of the original Medical Outcomes Survey<xref ref-type="bibr" rid="R34">34</xref> to measure functional impairment and contains eight subsections: (1) physical activity limitations due to health problems; (2) social activity limitations due to physical or emotional problems; (3) usual role activity limitations due to physical health problems; (4) bodily pain; (5) general mental health; (6) role activity limitations due to emotional problems; (7) vitality (energy and fatigue) and (8) general health perceptions.<xref ref-type="bibr" rid="R34">34</xref> The items are scored so that higher scores indicate a greater functional ability. In terms of the psychometric properties of this measure, reliability estimates for all subscales are good, exceeding the Cronbach's &#x003b1;-coefficient value of 0.70.<xref ref-type="bibr" rid="R35">35</xref> In terms of validity, the Short-Form (SF-36) correlates amply, r&#x02265;0.40, with the frequency and severity of numerous symptoms and general health conditions.<xref ref-type="bibr" rid="R36">36</xref>
<xref ref-type="bibr" rid="R37">37</xref></p></sec><sec id="s2b2"><title>Multidimensional Fatigue Inventory</title><p>This 20-item measure contains five fatigue dimensions: general fatigue, physical fatigue, mental fatigue, reduced motivation and reduced activity.<xref ref-type="bibr" rid="R38">38</xref> Items such as &#x02018;I tire easily&#x02019; are rated on a five-point scale (1=yes, that is true; 5=no, that is not true) with lower scores reflecting higher levels of fatigue. The Multidimensional Fatigue Inventory (MFI) has good internal consistency with average Cronbach's &#x003b1;-coefficient equalling 0.84 across the subscales. Convergent validity based on a sample of radiotherapy patients found correlations between the subscales and a visual analogue fatigue scale to be 0.77 for general fatigue, 0.70 for physical fatigue, 0.61 for reduced activity, 0.56 for reduced motivation (p&#x0003c;0.001) to 0.23 for mental fatigue (p&#x0003c;0.01).<xref ref-type="bibr" rid="R38">38</xref></p></sec></sec><sec id="s2c"><title>Secondary outcome measures</title><sec id="s2c1"><title>CDC CFS Symptom Inventory</title><p>CDC CFS Symptom Inventory<xref ref-type="bibr" rid="R39">39</xref> was used to measure specific ME/CFS symptoms and confirm diagnosis. This instrument is based upon the CDC case definition<xref ref-type="bibr" rid="R1">1</xref> and includes a fatigue item and the eight distinct symptoms are also included in the CDC guidelines with an additional 10 associated symptoms. The format of this self-report measure is a six-point scale of perceived frequency (0=absent, 5=all the time) and severity (0=none, 5=very severe). The psychometric properties of this instrument are good: the Cronbach's &#x003b1;-coefficient=0.88; r=0.74 convergent validity with the Chalder Fatigue Scale;<xref ref-type="bibr" rid="R40">40</xref> r &#x02212;0.68 and &#x02212;0.87 convergent validity with the SF-36 &#x02018;vitality&#x02019; and &#x02018;bodily pain&#x02019; subscales, respectively.</p></sec><sec id="s2c2"><title>Multidimensional Health Locus of Control Scale</title><p>Multidimensional Health Locus of Control Scale (MHLCS)<xref ref-type="bibr" rid="R41 R42 R43">41&#x02013;43</xref> measures perceived control via three distinct subscales: &#x02018;internal&#x02019;, &#x02018;chance&#x02019; and &#x02018;powerful others&#x02019; which has two dimensions, that of &#x02018;doctors&#x02019; and &#x02018;other people&#x02019;. The instrument contains 18 items in total (six items each for the &#x02018;internal&#x02019; and &#x02018;chance&#x02019; scales and three items for both the &#x02018;powerful others&#x02019; scales) and is scored on a 6-point Likert scale from &#x02018;strongly agree&#x02019; to &#x02018;strongly disagree&#x02019;. Internal reliability of the instrument is good with Cronbach's &#x003b1;-coefficients ranging from 0.67 for &#x02018;powerful others&#x02019; to 0.77 for &#x02018;internal&#x02019;. The measure correlates positively and significantly with associated scales from Levenson's<xref ref-type="bibr" rid="R44">44</xref> locus of control measure upon which the MHLOC was based, which demonstrates a good convergent validity.<xref ref-type="bibr" rid="R41">41</xref></p></sec></sec></sec><sec id="s3"><title>Statistical methods</title><p>The data were initially screened for missing data. Four cases contained substantial amounts of missing data; therefore these were excluded from the analysis (one individual from the nutrition group and three from the combined group). Subsequent analyses were conducted on complete date only. The baseline data were subsequently of the quality for parametric tests, except for the variables CDC CFS swollen lymph nodes and glands, memory problems, abdominal pain and depression. However, the follow-up data suffered from high levels of skew and kurtosis which was not substantially alleviated by data transformation. This violated a key criterion for parametric testing, that of normality of distribution, so non-parametric tests were selected. In addition, as the sample sizes in each individual treatment group were small, the more conservative non-parametric tests were the preferred choice as even though tests such as analysis of variance are generally robust against non-normality, this does not hold true with small sample sizes. One-way analysis of variance tests and Kruskal-Wallis tests (the former for those variables that met the criteria for parametric tests, and the latter that did not) were used to investigate baseline variation and analysis of covariance tests were used to account for this variation and test for differences among the three groups. Wilcoxon sign-rank tests were employed to look for differences over time (baseline and 3-month follow-up) and if differences were significant, percentage change was calculated. Please note, as this is an exploratory study with only one time-point and no control group, any significant findings do not infer clinical significance, rather statistical significance, and as such exact p values are presented.</p></sec><sec sec-type="results" id="s4"><title>Results</title><sec id="s4a"><title>Participants</title><p>Of the 145 individuals who expressed an interest in the study, 142 time-one questionnaires were returned, equating a 97.9% response rate at baseline (two participants from the psychology group and one from the combined group dropped out at this stage). Therefore, excluding the four cases deleted due to insufficient data, 138 cases were used for the baseline analysis; 42 participants in the psychology group, 44 in the nutrition group and 52 in the combined group. There was no significant association between gender and group (<italic>&#x003c7;</italic><sup>2</sup> (2)=0.179, p=0.915), all groups consisting of approximately one-fifth males (<xref ref-type="table" rid="BMJOPEN2012001079TB1">table 1</xref>). There was no significant difference in age (F(2, 135)=0.001, p=1.000); in fact group means for age were near identical at 42.881, 42.864 and 42.843 for psychology, nutrition and combined groups, respectively. There was also a non-significant result for illness duration (F(2, 135)=0.252, p=0.778). Therefore, in terms of demographics, the groups were comparable. With regard to the outcome measures, there were significant differences between the groups in terms of the MFI subscale &#x02018;general fatigue&#x02019; (F(2, 135)=3.219, p=0.043), MFI &#x02018;physical fatigue&#x02019; (F(2, 135)=3.343, p=0.038) and the CDC CFS symptom &#x02018;swollen lymph nodes and glands&#x02019; (H(2)=7.161, p=0.028). To investigate the source of these differences, post hoc tests were conducted (unrelated t tests for the fatigue variables and Mann-Whitney tests for swollen lymph glands as the former did not meet criteria for parametric tests, all with Bonferroni correction for multiple comparisons). A significant difference was observed between the psychology and combined groups with regard to general fatigue (t(92)=&#x02212;2.449, p=0.016) and physical fatigue (t(92)=&#x02212;2.658, p=0.009) and also between the nutrition and psychology groups in terms of the degree of lymph node and gland swelling (U=635.00, p=0.009). Within the fatigue measures, the combined group reported significantly higher levels of both general and physical fatigue than the psychology group, whereas those undertaking nutritional support stated a higher occurrence of swollen lymph nodes and glands.</p><table-wrap id="BMJOPEN2012001079TB1" position="float"><label>Table&#x000a0;1</label><caption><p>Demographics for gender, age and illness duration across the three treatment groups</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th colspan="3" rowspan="1">95% CI for mean<hr/></th><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Mean</th><th rowspan="1" colspan="1">SD</th><th rowspan="1" colspan="1">Lower</th><th rowspan="1" colspan="1">Upper</th><th rowspan="1" colspan="1">Test statistic</th><th rowspan="1" colspan="1">p Value</th></tr></thead><tbody><tr><td rowspan="4" colspan="1">Gender</td><td rowspan="1" colspan="1">Psychology</td><td rowspan="1" colspan="1">9 (21.4%)<sup>d</sup></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.179<sup>c</sup></td><td rowspan="1" colspan="1">0.915</td></tr><tr><td rowspan="1" colspan="1">Nutrition</td><td rowspan="1" colspan="1">8 (18.2%)<sup>d</sup></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Combined</td><td rowspan="1" colspan="1">11 (21.2%)<sup>d</sup></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1">28 (20.3%)<sup>d</sup></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="4" colspan="1">Age</td><td rowspan="1" colspan="1">Psychology</td><td rowspan="1" colspan="1">42.881</td><td rowspan="1" colspan="1">13.986</td><td rowspan="1" colspan="1">38.523</td><td rowspan="1" colspan="1">47.239</td><td rowspan="1" colspan="1">0.000<sup>a</sup></td><td rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">Nutrition</td><td rowspan="1" colspan="1">42.864</td><td rowspan="1" colspan="1">12.504</td><td rowspan="1" colspan="1">39.062</td><td rowspan="1" colspan="1">46.665</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Combined</td><td rowspan="1" colspan="1">42.843</td><td rowspan="1" colspan="1">11.125</td><td rowspan="1" colspan="1">39.714</td><td rowspan="1" colspan="1">45.972</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1">42.861</td><td rowspan="1" colspan="1">12.406</td><td rowspan="1" colspan="1">40.765</td><td rowspan="1" colspan="1">44.957</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="4" colspan="1">Illness duration</td><td rowspan="1" colspan="1">Psychology</td><td rowspan="1" colspan="1">8.874</td><td rowspan="1" colspan="1">8.252</td><td rowspan="1" colspan="1">6.302</td><td rowspan="1" colspan="1">11.445</td><td rowspan="1" colspan="1">0.252<sup>a</sup></td><td rowspan="1" colspan="1">0.778</td></tr><tr><td rowspan="1" colspan="1">Nutrition</td><td rowspan="1" colspan="1">10.023</td><td rowspan="1" colspan="1">7.375</td><td rowspan="1" colspan="1">7.781</td><td rowspan="1" colspan="1">12.265</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Combined</td><td rowspan="1" colspan="1">9.625</td><td rowspan="1" colspan="1">7.291</td><td rowspan="1" colspan="1">7.595</td><td rowspan="1" colspan="1">11.655</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1">9.523</td><td rowspan="1" colspan="1">7.580</td><td rowspan="1" colspan="1">8.247</td><td rowspan="1" colspan="1">10.800</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>(a), c F statistic for one-way analysis of variance; (c), b &#x003c7;<sup>2</sup> statistic; (d), a number of males.</p></fn></table-wrap-foot></table-wrap><sec id="s4a1"><title>Retention analysis</title><p>Seventy-two of the original 138 participants (14 participants in the psychology group, 27 in the nutrition group and 31 in the combined group) completed the battery of measures at the 3-month follow-up, resulting in retention rates of 52.17% in the study overall, 33.33% in the psychology group, 61.36% in the nutrition group and 59.62% in the combined group. To investigate whether the individuals who did not complete the time-two measures were significantly different from those at baseline on demographic and outcome measures, a series of t tests and Mann-Whitney tests were performed. Those that dropped out of the research (although still receiving treatment at the clinic) differed significantly in terms of age (t(136)=&#x02212;2.227, p=0.028) and illness duration (t(136)=&#x02212;2.549, p=0.012). Those who remained in the study were of significantly older age (mean age of those that remained in the study=45.056, SD=11.535; mean age of drop-outs=40.400, SD=12.932) and longer illness duration than those who dropped out (mean age of those that remained in the study=10.836, SD=7.383; mean illness duration of drop-outs=7.571, SD=7.472). Individuals who did not remain in the study did not differ significantly in terms of gender (<italic>&#x003c7;</italic><sup>2</sup> (2)=1.222, p=0.269) or any of the outcome measures.</p></sec></sec><sec id="s4b"><title>Comparisons within groups across time</title><sec id="s4b1"><title>Overall sample</title><sec id="s4b1a"><title>Primary outcomes</title><p>The following percentage change scores represent statistically significant changes, rather than clinically significant shifts, as this was an exploratory study. In the sample as a whole, there were improvements in all areas of the SF-36 (<xref ref-type="table" rid="BMJOPEN2012001079TB2">table 2</xref>), with a 5.80% improvement in physical functioning, a 68.98% improvement in role limitations due to physical difficulties, a 5.17% improvement in bodily pain, a 26.17% improvement in social functioning, a 5.77% improvement in general mental health, a 10.58% improvement in role limitations due to emotional difficulties, a 22.30% improvement in vitality, energy or fatigue and a 36.49% improvement in general health perception. When looking at the fatigue subscales of the MFI, all five subscales showed significant reductions in fatigue; 8.55% in general fatigue, 10.98% in physical fatigue, 8.81% in reduced activity, 12.96% in reduced motivation and 12.79% in mental fatigue.</p><table-wrap id="BMJOPEN2012001079TB2" position="float"><label>Table&#x000a0;2</label><caption><p>Comparisons across time within the primary outcome measures within the overall sample</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">N</th><th colspan="3" rowspan="1">Baseline<hr/></th><th colspan="3" rowspan="1">3-Month follow-up<hr/></th><th colspan="2" rowspan="1">Comparisons<hr/></th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th colspan="3" rowspan="1">Percentiles<hr/></th><th colspan="3" rowspan="1">Percentiles<hr/></th><th rowspan="1" colspan="1">z Statistic</th><th rowspan="1" colspan="1">p Value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Lower</td><td align="left" rowspan="1" colspan="1">Mdn</td><td align="left" rowspan="1" colspan="1">Upper</td><td align="left" rowspan="1" colspan="1">Lower</td><td align="left" rowspan="1" colspan="1">Mdn</td><td align="left" rowspan="1" colspan="1">Upper</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">SF-36 physical functioning</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">18.075</td><td rowspan="1" colspan="1">41.644</td><td rowspan="1" colspan="1">66.667</td><td rowspan="1" colspan="1">25.694</td><td rowspan="1" colspan="1">47.222</td><td rowspan="1" colspan="1">77.583</td><td rowspan="1" colspan="1">&#x02212;3.120</td><td rowspan="1" colspan="1">0.002**</td></tr><tr><td rowspan="1" colspan="1">SF-36 role limitations physical</td><td rowspan="1" colspan="1">71</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1">&#x02212;4.321</td><td rowspan="1" colspan="1">0.001***</td></tr><tr><td rowspan="1" colspan="1">SF-36 bodily pain</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">32.5</td><td rowspan="1" colspan="1">56.25</td><td rowspan="1" colspan="1">79.375</td><td rowspan="1" colspan="1">32.500</td><td rowspan="1" colspan="1">67.500</td><td rowspan="1" colspan="1">90</td><td rowspan="1" colspan="1">&#x02212;2.240</td><td rowspan="1" colspan="1">0.025*</td></tr><tr><td rowspan="1" colspan="1">SF-36 social functioning</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">12.5</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1">12.500</td><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1">75</td><td rowspan="1" colspan="1">&#x02212;4.504</td><td rowspan="1" colspan="1">0.001***</td></tr><tr><td rowspan="1" colspan="1">SF-36 general mental health</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">53</td><td rowspan="1" colspan="1">60</td><td rowspan="1" colspan="1">75</td><td rowspan="1" colspan="1">57</td><td rowspan="1" colspan="1">68</td><td rowspan="1" colspan="1">80</td><td rowspan="1" colspan="1">&#x02212;2.665</td><td rowspan="1" colspan="1">0.008**</td></tr><tr><td rowspan="1" colspan="1">SF-36 role limitations emotional</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">33.317</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">41.667</td><td rowspan="1" colspan="1">66.670</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">&#x02212;3.159</td><td rowspan="1" colspan="1">0.002**</td></tr><tr><td rowspan="1" colspan="1">SF-36 vitality energy or fatigue</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">11.250</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">45</td><td rowspan="1" colspan="1">&#x02212;4.205</td><td rowspan="1" colspan="1">0.001***</td></tr><tr><td rowspan="1" colspan="1">SF-36 general health perceptions</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1">&#x02212;3.996</td><td rowspan="1" colspan="1">0.001***</td></tr><tr><td rowspan="1" colspan="1">MFI general fatigue</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">&#x02212;3.692</td><td rowspan="1" colspan="1">0.001***</td></tr><tr><td rowspan="1" colspan="1">MFI physical fatigue</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">&#x02212;4.591</td><td rowspan="1" colspan="1">0.001***</td></tr><tr><td rowspan="1" colspan="1">MFI reduced activity</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">&#x02212;2.421</td><td rowspan="1" colspan="1">0.015*</td></tr><tr><td rowspan="1" colspan="1">MFI reduced motivation</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">13.750</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">&#x02212;2.986</td><td rowspan="1" colspan="1">0.003**</td></tr><tr><td rowspan="1" colspan="1">MFI mental fatigue</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">8.250</td><td rowspan="1" colspan="1">12.500</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">&#x02212;3.661</td><td rowspan="1" colspan="1">0.001***</td></tr></tbody></table><table-wrap-foot><fn><p><bold>*</bold>Significant at 0.05 level.</p></fn><fn><p><bold>*</bold>*Significant at 0.01 level.</p></fn><fn><p><bold>*</bold>**Significant at 0.001 level.</p></fn><fn><p>Mdn, median; MFI, Multidimensional Fatigue Inventory; SF-36, Short-Form 36.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s4b1b"><title>Secondary outcomes</title><p>Within the CFS Symptom Inventory (<xref ref-type="table" rid="BMJOPEN2012001079TB3">table 3</xref>), there were improvements in occurrence of sore throats (34.48%), diarrhoea (42.47%), fatigue after exertion (16.32%), muscle aches or muscle pains (21.01%), pain in joints (34.55%), chills (37.00%), unrefreshing sleep (19.55%), sleeping problems (17.17%), headaches (24.94%), memory problems (17.86%), difficulty concentrating (26.66%), sinus and nasal symptoms (26.38%), shortness of breath (29.28%), sensitivity to light (28.62%) and depression (39.55%). There were no significant differences from time-one to time-two in the MHLCS subscale of &#x02018;chance&#x02019;, &#x02018;powerful others&#x02019; and &#x02018;other people&#x02019; (<xref ref-type="table" rid="BMJOPEN2012001079TB3">table 3</xref>); however, the MHLCS did illustrate significant increases in internal locus of control (30.67%) and that of doctors (47.49%).</p><table-wrap id="BMJOPEN2012001079TB3" position="float"><label>Table&#x000a0;3</label><caption><p>Comparisons across time within the secondary outcome measures within the overall sample</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">N</th><th colspan="3" rowspan="1">Baseline<hr/></th><th colspan="3" rowspan="1">3-Month follow-up<hr/></th><th colspan="2" rowspan="1">Comparisons<hr/></th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th colspan="3" rowspan="1">Percentiles<hr/></th><th colspan="3" rowspan="1">Percentiles<hr/></th><th rowspan="1" colspan="1">z Statistic</th><th rowspan="1" colspan="1">p Value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Lower</td><td rowspan="1" colspan="1">Mdn</td><td align="left" rowspan="1" colspan="1">Upper</td><td rowspan="1" colspan="1">Lower</td><td align="left" rowspan="1" colspan="1">Mdn</td><td align="left" rowspan="1" colspan="1">Upper</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">CDC CFS sore throat</td><td rowspan="1" colspan="1">70</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1.5</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">&#x02212;2.257</td><td rowspan="1" colspan="1">0.024*</td></tr><tr><td rowspan="1" colspan="1">CDC CFS swollen lymph nodes/glands</td><td rowspan="1" colspan="1">71</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">&#x02212;1.567</td><td rowspan="1" colspan="1">0.115</td></tr><tr><td rowspan="1" colspan="1">CDC CFS diarrhoea</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">&#x02212;2.481</td><td rowspan="1" colspan="1">0.013*</td></tr><tr><td rowspan="1" colspan="1">CDC CFS fatigue after exertion</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">6.500</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">&#x02212;3.574</td><td rowspan="1" colspan="1">0.001***</td></tr><tr><td rowspan="1" colspan="1">CDC CFS muscle aches/pains</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">1.250</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">&#x02212;3.995</td><td rowspan="1" colspan="1">0.001***</td></tr><tr><td rowspan="1" colspan="1">CDC CFS pain in joints</td><td rowspan="1" colspan="1">70</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">&#x02212;2.908</td><td rowspan="1" colspan="1">0.004**</td></tr><tr><td rowspan="1" colspan="1">CDC CFS fever</td><td rowspan="1" colspan="1">70</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x02212;1.667</td><td rowspan="1" colspan="1">0.095</td></tr><tr><td rowspan="1" colspan="1">CDC CFS chills</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2.113</td><td rowspan="1" colspan="1">&#x02212;4.206</td><td rowspan="1" colspan="1">0.001***</td></tr><tr><td rowspan="1" colspan="1">CDC CFS unrefreshing sleep</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">&#x02212;2.295</td><td rowspan="1" colspan="1">0.022*</td></tr><tr><td rowspan="1" colspan="1">CDC CFS sleeping problems</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">&#x02212;1.983</td><td rowspan="1" colspan="1">0.047*</td></tr><tr><td rowspan="1" colspan="1">CDC CFS headaches</td><td rowspan="1" colspan="1">71</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">11.250</td><td rowspan="1" colspan="1">&#x02212;2.850</td><td rowspan="1" colspan="1">0.004**</td></tr><tr><td rowspan="1" colspan="1">CDC CFS memory problems</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">11.250</td><td rowspan="1" colspan="1">&#x02212;2.053</td><td rowspan="1" colspan="1">0.040*</td></tr><tr><td rowspan="1" colspan="1">CDC CFS difficulty concentrating</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">2.500</td><td rowspan="1" colspan="1">8.500</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">&#x02212;3.440</td><td rowspan="1" colspan="1">0.001***</td></tr><tr><td rowspan="1" colspan="1">CDC CFS nausea</td><td rowspan="1" colspan="1">71</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">&#x02212;0.898</td><td rowspan="1" colspan="1">0.369</td></tr><tr><td rowspan="1" colspan="1">CDC CFS abdominal pain</td><td rowspan="1" colspan="1">71</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">&#x02212;1.932</td><td rowspan="1" colspan="1">0.053</td></tr><tr><td rowspan="1" colspan="1">CDC CFS sinus nasal symptoms</td><td rowspan="1" colspan="1">71</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">&#x02212;2.862</td><td rowspan="1" colspan="1">0.004**</td></tr><tr><td rowspan="1" colspan="1">CDC CFS shortness of breath</td><td rowspan="1" colspan="1">69</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">&#x02212;2.402</td><td rowspan="1" colspan="1">0.016*</td></tr><tr><td rowspan="1" colspan="1">CDC CFS sensitivity to light</td><td rowspan="1" colspan="1">71</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">&#x02212;2.388</td><td rowspan="1" colspan="1">0.017*</td></tr><tr><td rowspan="1" colspan="1">CDC CFS depression</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">&#x02212;2.297</td><td rowspan="1" colspan="1">0.022*</td></tr><tr><td rowspan="1" colspan="1">MHLCS internal</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">0.528</td><td rowspan="1" colspan="1">0.681</td><td rowspan="1" colspan="1">0.799</td><td rowspan="1" colspan="1">0.611</td><td rowspan="1" colspan="1">0.722</td><td rowspan="1" colspan="1">0.889</td><td rowspan="1" colspan="1">&#x02212;2.962</td><td rowspan="1" colspan="1">0.003**</td></tr><tr><td rowspan="1" colspan="1">MHLCS chance</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">0.222</td><td rowspan="1" colspan="1">0.344</td><td rowspan="1" colspan="1">0.417</td><td rowspan="1" colspan="1">0.201</td><td rowspan="1" colspan="1">0.320</td><td rowspan="1" colspan="1">0.444</td><td rowspan="1" colspan="1">&#x02212;1.552</td><td rowspan="1" colspan="1">0.121</td></tr><tr><td rowspan="1" colspan="1">MHLCS powerful others</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">0.333</td><td rowspan="1" colspan="1">0.389</td><td rowspan="1" colspan="1">0.500</td><td rowspan="1" colspan="1">0.306</td><td rowspan="1" colspan="1">0.361</td><td rowspan="1" colspan="1">0.500</td><td rowspan="1" colspan="1">&#x02212;1.601</td><td rowspan="1" colspan="1">0.109</td></tr><tr><td rowspan="1" colspan="1">MHLCS doctors</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">0.0833</td><td rowspan="1" colspan="1">0.139</td><td rowspan="1" colspan="1">0.222</td><td rowspan="1" colspan="1">0.083</td><td rowspan="1" colspan="1">0.111</td><td rowspan="1" colspan="1">0.194</td><td rowspan="1" colspan="1">&#x02212;2.381</td><td rowspan="1" colspan="1">0.017*</td></tr><tr><td rowspan="1" colspan="1">MHLCS other people</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">0.194</td><td rowspan="1" colspan="1">0.250</td><td rowspan="1" colspan="1">0.3056</td><td rowspan="1" colspan="1">0.174</td><td rowspan="1" colspan="1">0.250</td><td rowspan="1" colspan="1">0.278</td><td rowspan="1" colspan="1">&#x02212;1.186</td><td rowspan="1" colspan="1">0.236</td></tr></tbody></table><table-wrap-foot><fn><p><bold>*</bold>Significant at 0.05 level.</p></fn><fn><p><bold>*</bold>*Significant at 0.01 level.</p></fn><fn><p><bold>*</bold>**Significant at 0.001 level.</p></fn><fn><p>CDC CFS, Centers for Disease Control Chronic Fatigue Syndrome Inventory; CFS, chronic fatigue syndrome; Mdn, median; MHLCS, Multidimensional Health Locus of Control Scale.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s4b2"><title>Psychology group</title><sec id="s4b2a"><title>Primary outcomes</title><p>Within the group of individuals who opted for a purely psychological intervention, improvements were seen in physical functioning (16.75%), role limitations due to physical problems (84.61%), social functioning (37.81%), general mental health (19.15%), vitality, energy or fatigue (49.57%) and general health perceptions (19.01%). Also, all the MFI fatigue scales decreased over a 3-month period, 13.58% in general fatigue, 17.74% in physical fatigue, 23.20% in reduced activity, 11.42% in reduced motivation and 29.66% in mental fatigue (<xref ref-type="table" rid="BMJOPEN2012001079TB4">table 4</xref>).</p><table-wrap id="BMJOPEN2012001079TB4" position="float"><label>Table&#x000a0;4</label><caption><p>Comparisons across time within the primary outcome measures within the psychology group</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">N</th><th colspan="3" rowspan="1">Baseline<hr/></th><th colspan="3" rowspan="1">3-Month follow-up<hr/></th><th colspan="2" rowspan="1">Comparisons<hr/></th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th colspan="3" rowspan="1">Percentiles<hr/></th><th colspan="3" rowspan="1">Percentiles<hr/></th><th rowspan="1" colspan="1">z Statistic</th><th rowspan="1" colspan="1">p Value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Lower</td><td align="left" rowspan="1" colspan="1">Mdn</td><td align="left" rowspan="1" colspan="1">Upper</td><td align="left" rowspan="1" colspan="1">Lower</td><td align="left" rowspan="1" colspan="1">Mdn</td><td align="left" rowspan="1" colspan="1">Upper</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">SF-36 physical functioning</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">25.008</td><td rowspan="1" colspan="1">44.444</td><td rowspan="1" colspan="1">58.367</td><td rowspan="1" colspan="1">27.083</td><td rowspan="1" colspan="1">69.450</td><td rowspan="1" colspan="1">84.700</td><td rowspan="1" colspan="1">&#x02212;2.707</td><td rowspan="1" colspan="1">0.007**</td></tr><tr><td rowspan="1" colspan="1">SF-36 role limitations physical</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1">81.250</td><td rowspan="1" colspan="1">&#x02212;2.379</td><td rowspan="1" colspan="1">0.017*</td></tr><tr><td rowspan="1" colspan="1">SF-36 bodily pain</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">39.375</td><td rowspan="1" colspan="1">57.500</td><td rowspan="1" colspan="1">80.625</td><td rowspan="1" colspan="1">32.500</td><td rowspan="1" colspan="1">72.500</td><td rowspan="1" colspan="1">90</td><td rowspan="1" colspan="1">&#x02212;1.195</td><td rowspan="1" colspan="1">0.232</td></tr><tr><td rowspan="1" colspan="1">SF-36 social functioning</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">37.500</td><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1">34.375</td><td rowspan="1" colspan="1">56.250</td><td rowspan="1" colspan="1">90.625</td><td rowspan="1" colspan="1">&#x02212;2.689</td><td rowspan="1" colspan="1">0.007**</td></tr><tr><td rowspan="1" colspan="1">SF-36 general mental health</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">47</td><td rowspan="1" colspan="1">62</td><td rowspan="1" colspan="1">80</td><td rowspan="1" colspan="1">67</td><td rowspan="1" colspan="1">76</td><td rowspan="1" colspan="1">88</td><td rowspan="1" colspan="1">&#x02212;2.497</td><td rowspan="1" colspan="1">0.013*</td></tr><tr><td rowspan="1" colspan="1">SF-36 role limitations emotional</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">24.974</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">58.336</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">&#x02212;0.842</td><td rowspan="1" colspan="1">0.400</td></tr><tr><td rowspan="1" colspan="1">SF-36 vitality energy or fatigue</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">28.750</td><td rowspan="1" colspan="1">45</td><td rowspan="1" colspan="1">52.500</td><td rowspan="1" colspan="1">&#x02212;3.066</td><td rowspan="1" colspan="1">0.002**</td></tr><tr><td rowspan="1" colspan="1">SF-36 general health perceptions</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">23.750</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">41.250</td><td rowspan="1" colspan="1">31.250</td><td rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">63.750</td><td rowspan="1" colspan="1">&#x02212;2.561</td><td rowspan="1" colspan="1">0.010*</td></tr><tr><td rowspan="1" colspan="1">MFI general fatigue</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">16.500</td><td rowspan="1" colspan="1">18.500</td><td rowspan="1" colspan="1">9.750</td><td rowspan="1" colspan="1">13.500</td><td rowspan="1" colspan="1">18.500</td><td rowspan="1" colspan="1">&#x02212;2.657</td><td rowspan="1" colspan="1">0.008**</td></tr><tr><td rowspan="1" colspan="1">MFI physical fatigue</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">13.750</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">19.250</td><td rowspan="1" colspan="1">8.750</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">16.750</td><td rowspan="1" colspan="1">&#x02212;2.810</td><td rowspan="1" colspan="1">0.005**</td></tr><tr><td rowspan="1" colspan="1">MFI reduced activity</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">9.750</td><td rowspan="1" colspan="1">12.500</td><td rowspan="1" colspan="1">18.250</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">14.500</td><td rowspan="1" colspan="1">&#x02212;2.142</td><td rowspan="1" colspan="1">0.032*</td></tr><tr><td rowspan="1" colspan="1">MFI reduced motivation</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">5.750</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">11.750</td><td rowspan="1" colspan="1">4.750</td><td rowspan="1" colspan="1">5.500</td><td rowspan="1" colspan="1">8.250</td><td rowspan="1" colspan="1">&#x02212;2.131</td><td rowspan="1" colspan="1">0.033*</td></tr><tr><td rowspan="1" colspan="1">MFI mental fatigue</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">11.750</td><td rowspan="1" colspan="1">15.500</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">6.500</td><td rowspan="1" colspan="1">9.500</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">&#x02212;2.950</td><td rowspan="1" colspan="1">0.003*</td></tr></tbody></table><table-wrap-foot><fn><p><bold>*</bold>Significant at 0.05 level.</p></fn><fn><p><bold>*</bold>*Significant at 0.01 level.</p></fn><fn><p>Mdn, median; MFI, Multidimensional Fatigue Inventory; SF-36, Short-Form 36.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s4b2b"><title>Secondary outcomes</title><p>Within those taking part in the psychology intervention, ratings of muscle aches or muscle pains (10.34%), chills (23.40%), memory problems (44.73%), difficulty concentrating (39.50%) and sensitivity to light (64.58%) decreased. A significant increase of 17.56% was observed in internal locus of control, a decrease of 4.67% in the perception that chance played an influential part in the individuals&#x02019; lives (<xref ref-type="table" rid="BMJOPEN2012001079TB5">table 5</xref>).</p><table-wrap id="BMJOPEN2012001079TB5" position="float"><label>Table&#x000a0;5</label><caption><p>Comparisons across time within the secondary outcome measures within the psychology group</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">N</th><th colspan="3" rowspan="1">Baseline<hr/></th><th colspan="3" rowspan="1">3-Month follow-up<hr/></th><th colspan="2" rowspan="1">Comparisons<hr/></th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th colspan="3" rowspan="1">Percentiles<hr/></th><th colspan="3" rowspan="1">Percentiles<hr/></th><th rowspan="1" colspan="1">z Statistic</th><th rowspan="1" colspan="1">p Value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Lower</td><td rowspan="1" colspan="1">Mdn</td><td align="left" rowspan="1" colspan="1">Upper</td><td rowspan="1" colspan="1">Lower</td><td rowspan="1" colspan="1">Mdn</td><td align="left" rowspan="1" colspan="1">Upper</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">CDC CFS sore throat</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2.500</td><td rowspan="1" colspan="1">&#x02212;1.365</td><td rowspan="1" colspan="1">0.172</td></tr><tr><td rowspan="1" colspan="1">CDC CFS swollen lymph nodes/glands</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.5</td><td rowspan="1" colspan="1">2.5</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">&#x02212;0.341</td><td rowspan="1" colspan="1">0.733</td></tr><tr><td rowspan="1" colspan="1">CDC CFS diarrhoea</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2.500</td><td rowspan="1" colspan="1">&#x02212;0.730</td><td rowspan="1" colspan="1">0.465</td></tr><tr><td rowspan="1" colspan="1">CDC CFS fatigue after exertion</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">7.750</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">&#x02212;1.550</td><td rowspan="1" colspan="1">0.121</td></tr><tr><td rowspan="1" colspan="1">CDC CFS muscle aches/pains</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">15.25</td><td rowspan="1" colspan="1">1.750</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">&#x02212;2.145</td><td rowspan="1" colspan="1">0.032*</td></tr><tr><td rowspan="1" colspan="1">CDC CFS pain in joints</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2.5</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.500</td><td rowspan="1" colspan="1">4.500</td><td rowspan="1" colspan="1">&#x02212;1.778</td><td rowspan="1" colspan="1">0.075</td></tr><tr><td rowspan="1" colspan="1">CDC CFS fever</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1.5</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.500</td><td rowspan="1" colspan="1">&#x02212;0.135</td><td rowspan="1" colspan="1">0.892</td></tr><tr><td rowspan="1" colspan="1">CDC CFS chills</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">6.75</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">4.500</td><td rowspan="1" colspan="1">&#x02212;1.970</td><td rowspan="1" colspan="1">0.049*</td></tr><tr><td rowspan="1" colspan="1">CDC CFS unrefreshing sleep</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">15.25</td><td rowspan="1" colspan="1">5.500</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">&#x02212;0.802</td><td rowspan="1" colspan="1">0.422</td></tr><tr><td rowspan="1" colspan="1">CDC CFS sleeping problems</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">2.75</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">9.750</td><td rowspan="1" colspan="1">&#x02212;1.738</td><td rowspan="1" colspan="1">0.082</td></tr><tr><td rowspan="1" colspan="1">CDC CFS headaches</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">2.5</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">0.750</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">6.750</td><td rowspan="1" colspan="1">&#x02212;1.200</td><td rowspan="1" colspan="1">0.230</td></tr><tr><td rowspan="1" colspan="1">CDC CFS memory problems</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">0.750</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">6.750</td><td rowspan="1" colspan="1">&#x02212;1.965</td><td rowspan="1" colspan="1">0.049*</td></tr><tr><td rowspan="1" colspan="1">CDC CFS difficulty concentrating</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">3.5</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">6.750</td><td rowspan="1" colspan="1">&#x02212;2.809</td><td rowspan="1" colspan="1">0.005**</td></tr><tr><td rowspan="1" colspan="1">CDC CFS nausea</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">4.25</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">4.500</td><td rowspan="1" colspan="1">&#x02212;0.213</td><td rowspan="1" colspan="1">0.832</td></tr><tr><td rowspan="1" colspan="1">CDC CFS abdominal pain</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">5.25</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">&#x02212;0.343</td><td rowspan="1" colspan="1">0.732</td></tr><tr><td rowspan="1" colspan="1">CDC CFS sinus nasal symptoms</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">3.5</td><td rowspan="1" colspan="1">4.5</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1.500</td><td rowspan="1" colspan="1">4.500</td><td rowspan="1" colspan="1">&#x02212;0.724</td><td rowspan="1" colspan="1">0.469</td></tr><tr><td rowspan="1" colspan="1">CDC CFS shortness of breath</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1.5</td><td rowspan="1" colspan="1">4.5</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.500</td><td rowspan="1" colspan="1">2.50</td><td rowspan="1" colspan="1">&#x02212;1.556</td><td rowspan="1" colspan="1">0.120</td></tr><tr><td rowspan="1" colspan="1">CDC CFS sensitivity to light</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">4.5</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1.250</td><td rowspan="1" colspan="1">&#x02212;1.973</td><td rowspan="1" colspan="1">0.049*</td></tr><tr><td rowspan="1" colspan="1">CDC CFS depression</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1.5</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">&#x02212;1.614</td><td rowspan="1" colspan="1">0.106</td></tr><tr><td rowspan="1" colspan="1">MHLCS internal</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">0.556</td><td rowspan="1" colspan="1">0.653</td><td rowspan="1" colspan="1">0.840</td><td rowspan="1" colspan="1">0.611</td><td rowspan="1" colspan="1">0.872</td><td rowspan="1" colspan="1">0.923</td><td rowspan="1" colspan="1">&#x02212;2.983</td><td rowspan="1" colspan="1">0.003**</td></tr><tr><td rowspan="1" colspan="1">MHLCS chance</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">0.326</td><td rowspan="1" colspan="1">0.417</td><td rowspan="1" colspan="1">0.535</td><td rowspan="1" colspan="1">0.167</td><td rowspan="1" colspan="1">0.361</td><td rowspan="1" colspan="1">0.451</td><td rowspan="1" colspan="1">&#x02212;2.594</td><td rowspan="1" colspan="1">0.009**</td></tr><tr><td rowspan="1" colspan="1">MHLCS powerful others</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">0.319</td><td rowspan="1" colspan="1">0.375</td><td rowspan="1" colspan="1">0.451</td><td rowspan="1" colspan="1">0.299</td><td rowspan="1" colspan="1">0.356</td><td rowspan="1" colspan="1">0.431</td><td rowspan="1" colspan="1">0.000</td><td rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">MHLCS doctors</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">0.083</td><td rowspan="1" colspan="1">0.125</td><td rowspan="1" colspan="1">0.194</td><td rowspan="1" colspan="1">0.083</td><td rowspan="1" colspan="1">0.083</td><td rowspan="1" colspan="1">0.174</td><td rowspan="1" colspan="1">&#x02212;1.122</td><td rowspan="1" colspan="1">0.262</td></tr><tr><td rowspan="1" colspan="1">MHLCS other people</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">0.194</td><td rowspan="1" colspan="1">0.236</td><td rowspan="1" colspan="1">0.285</td><td rowspan="1" colspan="1">0.194</td><td rowspan="1" colspan="1">0.222</td><td rowspan="1" colspan="1">0.257</td><td rowspan="1" colspan="1">&#x02212;0.118</td><td rowspan="1" colspan="1">0.906</td></tr></tbody></table><table-wrap-foot><fn><p><bold>*</bold>Significant at 0.05 level.</p></fn><fn><p><bold>*</bold>*Significant at 0.01 level.</p></fn><fn><p>CDC CFS, Centers for Disease Control Chronic Fatigue Syndrome Inventory; CFS, chronic fatigue syndrome; Mdn, median; MHLCS, Multidimensional Health Locus of Control Scale.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s4b3"><title>Nutrition group</title><sec id="s4b3a"><title>Primary outcomes</title><p>The nutrition group saw improvements in role limitations due to physical problems (75.28%), social functioning (24.93%), vitality, energy or fatigue (35.35%) and general health perceptions (29.73%). Once again, all the MFI fatigue scales decreased over a 3-month period, 13.39% in general fatigue, 15.00% in physical fatigue, 13.28% in reduced activity, 14.64% in reduced motivation and 12.83% in mental fatigue (<xref ref-type="table" rid="BMJOPEN2012001079TB6">table 6</xref>).</p><table-wrap id="BMJOPEN2012001079TB6" position="float"><label>Table&#x000a0;6</label><caption><p>Comparisons across time within the primary outcome measures within the nutrition group</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">N</th><th colspan="3" rowspan="1">Baseline<hr/></th><th colspan="3" rowspan="1">3-Month follow-up<hr/></th><th colspan="2" rowspan="1">Comparisons<hr/></th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th colspan="3" rowspan="1">Percentiles<hr/></th><th colspan="3" rowspan="1">Percentiles<hr/></th><th rowspan="1" colspan="1">z Statistic</th><th rowspan="1" colspan="1">p Value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Lower</td><td align="left" rowspan="1" colspan="1">Mdn</td><td align="left" rowspan="1" colspan="1">Upper</td><td align="left" rowspan="1" colspan="1">Lower</td><td align="left" rowspan="1" colspan="1">Mdn</td><td align="left" rowspan="1" colspan="1">Upper</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">SF-36 physical functioning</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">16.7</td><td rowspan="1" colspan="1">44.444</td><td rowspan="1" colspan="1">77.778</td><td rowspan="1" colspan="1">16.700</td><td rowspan="1" colspan="1">38.889</td><td rowspan="1" colspan="1">77.778</td><td rowspan="1" colspan="1">&#x02212;1.136</td><td rowspan="1" colspan="1">0.256</td></tr><tr><td rowspan="1" colspan="1">SF-36 role limitations physical</td><td rowspan="1" colspan="1">26</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">&#x02212;2.878</td><td rowspan="1" colspan="1">0.004**</td></tr><tr><td rowspan="1" colspan="1">SF-36 bodily pain</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">32.5</td><td rowspan="1" colspan="1">45</td><td rowspan="1" colspan="1">67.5</td><td rowspan="1" colspan="1">35.200</td><td rowspan="1" colspan="1">67.500</td><td rowspan="1" colspan="1">90</td><td rowspan="1" colspan="1">&#x02212;1.800</td><td rowspan="1" colspan="1">0.072</td></tr><tr><td rowspan="1" colspan="1">SF-36 social functioning</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1">12.500</td><td rowspan="1" colspan="1">37.500</td><td rowspan="1" colspan="1">75</td><td rowspan="1" colspan="1">&#x02212;2.476</td><td rowspan="1" colspan="1">0.013*</td></tr><tr><td rowspan="1" colspan="1">SF-36 general mental health</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">52</td><td rowspan="1" colspan="1">60</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">52</td><td rowspan="1" colspan="1">64</td><td rowspan="1" colspan="1">80</td><td rowspan="1" colspan="1">&#x02212;1.696</td><td rowspan="1" colspan="1">0.090</td></tr><tr><td rowspan="1" colspan="1">SF-36 role limitations emotional</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">66.670</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">&#x02212;1.788</td><td rowspan="1" colspan="1">0.074</td></tr><tr><td rowspan="1" colspan="1">SF-36 vitality energy or fatigue</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">45</td><td rowspan="1" colspan="1">&#x02212;2.734</td><td rowspan="1" colspan="1">0.006**</td></tr><tr><td rowspan="1" colspan="1">SF-36 general health perceptions</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">45</td><td rowspan="1" colspan="1">&#x02212;2.157</td><td rowspan="1" colspan="1">0.031*</td></tr><tr><td rowspan="1" colspan="1">MFI general fatigue</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">&#x02212;2.548</td><td rowspan="1" colspan="1">0.011*</td></tr><tr><td rowspan="1" colspan="1">MFI physical fatigue</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">&#x02212;2.791</td><td rowspan="1" colspan="1">0.005**</td></tr><tr><td rowspan="1" colspan="1">MFI reduced activity</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">&#x02212;2.164</td><td rowspan="1" colspan="1">0.030*</td></tr><tr><td rowspan="1" colspan="1">MFI reduced motivation</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">&#x02212;1.985</td><td rowspan="1" colspan="1">0.047*</td></tr><tr><td rowspan="1" colspan="1">MFI mental fatigue</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">&#x02212;2.082</td><td rowspan="1" colspan="1">0.037*</td></tr></tbody></table><table-wrap-foot><fn><p><bold>*</bold>Significant at 0.05 level.</p></fn><fn><p><bold>*</bold>*Significant at 0.01 level.</p></fn><fn><p>Mdn, median; MFI, Multidimensional Fatigue Inventory; SF-36, Short-Form 36.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s4b3b"><title>Secondary outcomes</title><p>In the nutrition group, numerous symptom-related indices also showed improvements (<xref ref-type="table" rid="BMJOPEN2012001079TB7">table 7</xref>); sore throat (56.23%), swollen lymph glands (21.21%), fatigue after exertion (13.90%), muscle aches or muscle pains (20.56%), chills (40.74%), nausea (16.42%) and abdominal pain (20.16%). No significant differences were found from the baseline to follow-up in the perceived control (<xref ref-type="table" rid="BMJOPEN2012001079TB7">table 7</xref>).</p><table-wrap id="BMJOPEN2012001079TB7" position="float"><label>Table&#x000a0;7</label><caption><p>Comparisons across time within the secondary outcome measures within the nutrition group</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">N</th><th colspan="3" rowspan="1">Baseline<hr/></th><th colspan="3" rowspan="1">3-Month follow-up<hr/></th><th colspan="2" rowspan="1">Comparisons<hr/></th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th colspan="3" rowspan="1">Percentiles<hr/></th><th colspan="3" rowspan="1">Percentiles<hr/></th><th rowspan="1" colspan="1">z Statistic</th><th rowspan="1" colspan="1">p Value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Lower</td><td align="left" rowspan="1" colspan="1">Mdn</td><td align="left" rowspan="1" colspan="1">Upper</td><td align="left" rowspan="1" colspan="1">Lower</td><td align="left" rowspan="1" colspan="1">Mdn</td><td align="left" rowspan="1" colspan="1">Upper</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">CDC CFS sore throat</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">&#x02212;2.211</td><td rowspan="1" colspan="1">0.027*</td></tr><tr><td rowspan="1" colspan="1">CDC CFS swollen lymph nodes/glands</td><td rowspan="1" colspan="1">26</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">&#x02212;2.051</td><td rowspan="1" colspan="1">0.040*</td></tr><tr><td rowspan="1" colspan="1">CDC CFS diarrhoea</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x02212;1.649</td><td rowspan="1" colspan="1">0.099</td></tr><tr><td rowspan="1" colspan="1">CDC CFS fatigue after exertion</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">&#x02212;2.209</td><td rowspan="1" colspan="1">0.027*</td></tr><tr><td rowspan="1" colspan="1">CDC CFS muscle aches/pains</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">&#x02212;2.901</td><td rowspan="1" colspan="1">0.004**</td></tr><tr><td rowspan="1" colspan="1">CDC CFS pain in joints</td><td rowspan="1" colspan="1">26</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">0.750</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">&#x02212;1.827</td><td rowspan="1" colspan="1">0.068</td></tr><tr><td rowspan="1" colspan="1">CDC CFS fever</td><td rowspan="1" colspan="1">26</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x02212;1.254</td><td rowspan="1" colspan="1">0.210</td></tr><tr><td rowspan="1" colspan="1">CDC CFS chills</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#x02212;3.401</td><td rowspan="1" colspan="1">0.001***</td></tr><tr><td rowspan="1" colspan="1">CDC CFS unrefreshing sleep</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">&#x02212;1.421</td><td rowspan="1" colspan="1">0.155</td></tr><tr><td rowspan="1" colspan="1">CDC CFS sleeping problems</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">&#x02212;0.190</td><td rowspan="1" colspan="1">0.849</td></tr><tr><td rowspan="1" colspan="1">CDC CFS headaches</td><td rowspan="1" colspan="1">26</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">0.750</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">&#x02212;1.895</td><td rowspan="1" colspan="1">0.058</td></tr><tr><td rowspan="1" colspan="1">CDC CFS memory problems</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">&#x02212;0.338</td><td rowspan="1" colspan="1">0.735</td></tr><tr><td rowspan="1" colspan="1">CDC CFS difficulty concentrating</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">&#x02212;1.196</td><td rowspan="1" colspan="1">0.232</td></tr><tr><td rowspan="1" colspan="1">CDC CFS nausea</td><td rowspan="1" colspan="1">26</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">&#x02212;2.407</td><td rowspan="1" colspan="1">0.016*</td></tr><tr><td rowspan="1" colspan="1">CDC CFS abdominal pain</td><td rowspan="1" colspan="1">26</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">0.750</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">&#x02212;2.322</td><td rowspan="1" colspan="1">0.020*</td></tr><tr><td rowspan="1" colspan="1">CDC CFS sinus nasal symptoms</td><td rowspan="1" colspan="1">26</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">3.500</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">&#x02212;1.244</td><td rowspan="1" colspan="1">0.213</td></tr><tr><td rowspan="1" colspan="1">CDC CFS shortness of breath</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">&#x02212;1.651</td><td rowspan="1" colspan="1">0.099</td></tr><tr><td rowspan="1" colspan="1">CDC CFS sensitivity to light</td><td rowspan="1" colspan="1">26</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">&#x02212;1.890</td><td rowspan="1" colspan="1">0.059</td></tr><tr><td rowspan="1" colspan="1">CDC CFS depression</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">&#x02212;1.584</td><td rowspan="1" colspan="1">0.113</td></tr><tr><td rowspan="1" colspan="1">MHLCS internal</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">0.944</td><td rowspan="1" colspan="1">0.528</td><td rowspan="1" colspan="1">0.667</td><td rowspan="1" colspan="1">0.528</td><td rowspan="1" colspan="1">0.639</td><td rowspan="1" colspan="1">0.778</td><td rowspan="1" colspan="1">&#x02212;0.687</td><td rowspan="1" colspan="1">0.492</td></tr><tr><td rowspan="1" colspan="1">MHLCS chance</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">0.694</td><td rowspan="1" colspan="1">0.222</td><td rowspan="1" colspan="1">0.333</td><td rowspan="1" colspan="1">0.222</td><td rowspan="1" colspan="1">0.333</td><td rowspan="1" colspan="1">0.472</td><td rowspan="1" colspan="1">&#x02212;0.143</td><td rowspan="1" colspan="1">0.886</td></tr><tr><td rowspan="1" colspan="1">MHLCS powerful others</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">0.694</td><td rowspan="1" colspan="1">0.333</td><td rowspan="1" colspan="1">0.389</td><td rowspan="1" colspan="1">0.278</td><td rowspan="1" colspan="1">0.361</td><td rowspan="1" colspan="1">0.528</td><td rowspan="1" colspan="1">&#x02212;1.843</td><td rowspan="1" colspan="1">0.065</td></tr><tr><td rowspan="1" colspan="1">MHLCS doctors</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">0.417</td><td rowspan="1" colspan="1">0.0833</td><td rowspan="1" colspan="1">0.139</td><td rowspan="1" colspan="1">0.083</td><td rowspan="1" colspan="1">0.139</td><td rowspan="1" colspan="1">0.222</td><td rowspan="1" colspan="1">&#x02212;1.686</td><td rowspan="1" colspan="1">0.092</td></tr><tr><td rowspan="1" colspan="1">MHLCS other people</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">0.833</td><td rowspan="1" colspan="1">0.222</td><td rowspan="1" colspan="1">0.278</td><td rowspan="1" colspan="1">0.167</td><td rowspan="1" colspan="1">0.250</td><td rowspan="1" colspan="1">0.306</td><td rowspan="1" colspan="1">&#x02212;1.697</td><td rowspan="1" colspan="1">0.090</td></tr></tbody></table><table-wrap-foot><fn><p><bold>*</bold>Significant at 0.05 level.</p></fn><fn><p><bold>*</bold>*Significant at 0.01 level.</p></fn><fn><p><bold>*</bold>**Significant at 0.001 level.</p></fn><fn><p>CDC CFS, Centers for Disease Control Chronic Fatigue Syndrome Inventory; CFS, chronic fatigue syndrome; Mdn, median; MHLCS, Multidimensional Health Locus of Control Scale.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s4b4"><title>Combined group</title><sec id="s4b4a"><title>Primary outcomes</title><p>In terms of general health as gauged by the SF-36 measure, the group who received both psychological and nutritional intervention reported reductions in role limitations due to physical difficulties (57.02%), social functioning (22.61%), role limitations due to emotional difficulties (29.47%) and general health perceptions (26.45%). Only one measure of fatigue, that of physical fatigue, saw significant improvements over time (6.42%) in the combined group (<xref ref-type="table" rid="BMJOPEN2012001079TB8">table 8</xref>).</p><table-wrap id="BMJOPEN2012001079TB8" position="float"><label>Table&#x000a0;8</label><caption><p>Comparisons across time within the primary outcome measures within the combined group</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">N</th><th colspan="3" rowspan="1">Baseline<hr/></th><th colspan="3" rowspan="1">3-Month follow-up<hr/></th><th colspan="2" rowspan="1">Comparisons<hr/></th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th colspan="3" rowspan="1">Percentiles<hr/></th><th colspan="3" rowspan="1">Percentiles<hr/></th><th rowspan="1" colspan="1">z Statistic</th><th rowspan="1" colspan="1">p Value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Lower</td><td align="left" rowspan="1" colspan="1">Mdn</td><td align="left" rowspan="1" colspan="1">Upper</td><td align="left" rowspan="1" colspan="1">Lower</td><td align="left" rowspan="1" colspan="1">Mdn</td><td align="left" rowspan="1" colspan="1">Upper</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">SF-36 physical functioning</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">22.200</td><td rowspan="1" colspan="1">33.333</td><td rowspan="1" colspan="1">61.111</td><td rowspan="1" colspan="1">27.778</td><td rowspan="1" colspan="1">55.556</td><td rowspan="1" colspan="1">72.222</td><td rowspan="1" colspan="1">&#x02212;1.850</td><td rowspan="1" colspan="1">0.064</td></tr><tr><td rowspan="1" colspan="1">SF-36 role limitations physical</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">&#x02212;2.225</td><td rowspan="1" colspan="1">0.026*</td></tr><tr><td rowspan="1" colspan="1">SF-36 bodily pain</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">32.500</td><td rowspan="1" colspan="1">45</td><td rowspan="1" colspan="1">80</td><td rowspan="1" colspan="1">32.500</td><td rowspan="1" colspan="1">57.500</td><td rowspan="1" colspan="1">80</td><td rowspan="1" colspan="1">&#x02212;1.048</td><td rowspan="1" colspan="1">0.294</td></tr><tr><td rowspan="1" colspan="1">SF-36 social functioning</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">12.500</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">37.500</td><td rowspan="1" colspan="1">12.500</td><td rowspan="1" colspan="1">37.500</td><td rowspan="1" colspan="1">62.500</td><td rowspan="1" colspan="1">&#x02212;2.426</td><td rowspan="1" colspan="1">0.015*</td></tr><tr><td rowspan="1" colspan="1">SF-36 general mental health</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">56</td><td rowspan="1" colspan="1">60</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">56</td><td rowspan="1" colspan="1">68</td><td rowspan="1" colspan="1">76</td><td rowspan="1" colspan="1">&#x02212;0.524</td><td rowspan="1" colspan="1">0.600</td></tr><tr><td rowspan="1" colspan="1">SF-36 role limitations emotional</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">33.333</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">66.667</td><td rowspan="1" colspan="1">66.670</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">&#x02212;2.313</td><td rowspan="1" colspan="1">0.021*</td></tr><tr><td rowspan="1" colspan="1">SF-36 vitality energy or fatigue</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">&#x02212;1.558</td><td rowspan="1" colspan="1">0.119</td></tr><tr><td rowspan="1" colspan="1">SF-36 general health perceptions</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">55</td><td rowspan="1" colspan="1">&#x02212;2.423</td><td rowspan="1" colspan="1">0.015*</td></tr><tr><td rowspan="1" colspan="1">MFI general fatigue</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">&#x02212;0.854</td><td rowspan="1" colspan="1">0.393</td></tr><tr><td rowspan="1" colspan="1">MFI physical fatigue</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">&#x02212;2.364</td><td rowspan="1" colspan="1">0.018*</td></tr><tr><td rowspan="1" colspan="1">MFI reduced activity</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">&#x02212;0.070</td><td rowspan="1" colspan="1">0.944</td></tr><tr><td rowspan="1" colspan="1">MFI reduced motivation</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">&#x02212;1.082</td><td rowspan="1" colspan="1">0.279</td></tr><tr><td rowspan="1" colspan="1">MFI mental fatigue</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">&#x02212;1.586</td><td rowspan="1" colspan="1">0.113</td></tr></tbody></table><table-wrap-foot><fn><p><bold>*</bold>Significant at 0.05 level.</p></fn><fn><p>Mdn, median; MFI, Multidimensional Fatigue Inventory; SF-36, Short-Form 36.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s4b4b"><title>Secondary outcomes</title><p>Those in the combined group saw significant reductions over the 3-month interval in diarrhoea (47.97%), fatigue after exertion (19.20%), chills (40.23%), headaches (36.18%) and sinus and nasal symptoms (20.56%; <xref ref-type="table" rid="BMJOPEN2012001079TB9">table 9</xref>). No significant differences were found from the baseline to follow-up in the perceived control as measured by the MHLCS in the combined treatment group (<xref ref-type="table" rid="BMJOPEN2012001079TB9">table 9</xref>).</p><table-wrap id="BMJOPEN2012001079TB9" position="float"><label>Table&#x000a0;9</label><caption><p>Comparisons across time within the secondary outcome measures within the combined group</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">N</th><th colspan="3" rowspan="1">Baseline<hr/></th><th colspan="3" rowspan="1">3-Month follow-up<hr/></th><th colspan="2" rowspan="1">Comparisons<hr/></th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th colspan="3" rowspan="1">Percentiles<hr/></th><th colspan="3" rowspan="1">Percentiles<hr/></th><th rowspan="1" colspan="1">z Statistic</th><th rowspan="1" colspan="1">p Value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Lower</td><td align="left" rowspan="1" colspan="1">Mdn</td><td align="left" rowspan="1" colspan="1">Upper</td><td align="left" rowspan="1" colspan="1">Lower</td><td align="left" rowspan="1" colspan="1">Mdn</td><td align="left" rowspan="1" colspan="1">Upper</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">CDC CFS sore throat</td><td rowspan="1" colspan="1">29</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">3.500</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">2.030</td><td rowspan="1" colspan="1">&#x02212;0.567</td><td rowspan="1" colspan="1">0.571</td></tr><tr><td rowspan="1" colspan="1">CDC CFS swollen lymph nodes/glands</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">&#x02212;0.725</td><td rowspan="1" colspan="1">0.046</td></tr><tr><td rowspan="1" colspan="1">CDC CFS diarrhoea</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">&#x02212;1.996</td><td rowspan="1" colspan="1">0.046*</td></tr><tr><td rowspan="1" colspan="1">CDC CFS fatigue after exertion</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">&#x02212;2.392</td><td rowspan="1" colspan="1">0.017*</td></tr><tr><td rowspan="1" colspan="1">CDC CFS muscle aches/pains</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">&#x02212;1.908</td><td rowspan="1" colspan="1">0.056</td></tr><tr><td rowspan="1" colspan="1">CDC CFS pain in joints</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1.500</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">&#x02212;1.680</td><td rowspan="1" colspan="1">0.093</td></tr><tr><td rowspan="1" colspan="1">CDC CFS fever</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.720</td><td rowspan="1" colspan="1">&#x02212;1.383</td><td rowspan="1" colspan="1">0.167</td></tr><tr><td rowspan="1" colspan="1">CDC CFS chills</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">2.150</td><td rowspan="1" colspan="1">&#x02212;2.049</td><td rowspan="1" colspan="1">0.040*</td></tr><tr><td rowspan="1" colspan="1">CDC CFS unrefreshing sleep</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">&#x02212;1.513</td><td rowspan="1" colspan="1">0.130</td></tr><tr><td rowspan="1" colspan="1">CDC CFS sleeping problems</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">&#x02212;1.794</td><td rowspan="1" colspan="1">0.073</td></tr><tr><td rowspan="1" colspan="1">CDC CFS headaches</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">&#x02212;2.807</td><td rowspan="1" colspan="1">0.005**</td></tr><tr><td rowspan="1" colspan="1">CDC CFS memory problems</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">&#x02212;1.446</td><td rowspan="1" colspan="1">0.148</td></tr><tr><td rowspan="1" colspan="1">CDC CFS difficulty concentrating</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">&#x02212;1.899</td><td rowspan="1" colspan="1">0.058</td></tr><tr><td rowspan="1" colspan="1">CDC CFS nausea</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">&#x02212;0.855</td><td rowspan="1" colspan="1">0.392</td></tr><tr><td rowspan="1" colspan="1">CDC CFS abdominal pain</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">&#x02212;0.598</td><td rowspan="1" colspan="1">0.550</td></tr><tr><td rowspan="1" colspan="1">CDC CFS sinus nasal symptoms</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">&#x02212;2.482</td><td rowspan="1" colspan="1">0.013*</td></tr><tr><td rowspan="1" colspan="1">CDC CFS shortness of breath</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">&#x02212;0.976</td><td rowspan="1" colspan="1">0.329</td></tr><tr><td rowspan="1" colspan="1">CDC CFS sensitivity to light</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">&#x02212;0.787</td><td rowspan="1" colspan="1">0.431</td></tr><tr><td rowspan="1" colspan="1">CDC CFS depression</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">&#x02212;1.304</td><td rowspan="1" colspan="1">0.192</td></tr><tr><td rowspan="1" colspan="1">MHLCS internal</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">0.556</td><td rowspan="1" colspan="1">0.694</td><td rowspan="1" colspan="1">0.861</td><td rowspan="1" colspan="1">0.639</td><td rowspan="1" colspan="1">0.750</td><td rowspan="1" colspan="1">0.889</td><td rowspan="1" colspan="1">&#x02212;1.755</td><td rowspan="1" colspan="1">0.079</td></tr><tr><td rowspan="1" colspan="1">MHLCS chance</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">0.222</td><td rowspan="1" colspan="1">0.333</td><td rowspan="1" colspan="1">0.361</td><td rowspan="1" colspan="1">0.167</td><td rowspan="1" colspan="1">0.306</td><td rowspan="1" colspan="1">0.417</td><td rowspan="1" colspan="1">&#x02212;0.672</td><td rowspan="1" colspan="1">0.501</td></tr><tr><td rowspan="1" colspan="1">MHLCS powerful others</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">0.333</td><td rowspan="1" colspan="1">0.389</td><td rowspan="1" colspan="1">0.500</td><td rowspan="1" colspan="1">0.333</td><td rowspan="1" colspan="1">0.389</td><td rowspan="1" colspan="1">0.500</td><td rowspan="1" colspan="1">&#x02212;0.577</td><td rowspan="1" colspan="1">0.564</td></tr><tr><td rowspan="1" colspan="1">MHLCS doctors</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">0.111</td><td rowspan="1" colspan="1">0.167</td><td rowspan="1" colspan="1">0.222</td><td rowspan="1" colspan="1">0.083</td><td rowspan="1" colspan="1">0.139</td><td rowspan="1" colspan="1">0.500</td><td rowspan="1" colspan="1">&#x02212;1.384</td><td rowspan="1" colspan="1">0.166</td></tr><tr><td rowspan="1" colspan="1">MHLCS other people</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">0.167</td><td rowspan="1" colspan="1">0.250</td><td rowspan="1" colspan="1">0.278</td><td rowspan="1" colspan="1">0.194</td><td rowspan="1" colspan="1">0.250</td><td rowspan="1" colspan="1">0.306</td><td rowspan="1" colspan="1">&#x02212;0.213</td><td rowspan="1" colspan="1">0.831</td></tr></tbody></table><table-wrap-foot><fn><p>*Significant at 0.05 level.</p></fn><fn><p>**Significant at 0.01 level.</p></fn><fn><p>***Significant at 0.001 level.</p></fn><fn><p>CFS, chronic fatigue syndrome; Mdn, median; MHLCS, Multidimensional Health Locus of Control Scale.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s4b5"><title>Comparisons across groups</title><p>With correction for baseline variation, there were no significant differences between the three groups in terms of change scores.</p></sec></sec></sec><sec sec-type="discussion" id="s5"><title>Discussion</title><sec id="s5a"><title>Key results</title><p>There were statistically significant (rather than known clinically significant) changes over time of numerous measures in all groups investigated. However, this is not to say that these changes were due to the interventions as the design of this study was exploratory, rather than experimental (please see the following sections for a further critique of the design). The psychology group contained the most significant findings, including those concerned with daily functioning, fatigue, locus of control and cognitive CDC CFS-specific symptoms. These findings appear consistent with outcomes from other psychological interventions.<xref ref-type="bibr" rid="R3">3</xref>
<xref ref-type="bibr" rid="R4">4</xref>
<xref ref-type="bibr" rid="R6">6</xref> As expected, changes in the perceived control were not observed in the nutrition group as this is not an area that is targeted in this programme. However, the more immune-type symptoms such as sore throat and swollen lymph nodes or glands did see significant reductions over time as would be envisaged in treatment protocols based upon nutritional expertise. The group that exhibited the least significant findings was the combined group and, as noted below, this may be due to the greater general severity of symptoms in this group and the need for a more lengthy intervention. Nevertheless, considering the small sample sizes in the groups at the follow-up, these results are very promising and warrant further attention.</p></sec><sec id="s5b"><title>Interpretation</title><p>As noted previously<xref ref-type="bibr" rid="R31">31</xref> individualised treatment protocols which include a range of tailored strategies are a favourable direction for dealing with a complex and multisystem disorder such as ME/CFS. The present study has demonstrated that such interventions may be useful in lowering symptomatology, improving functioning and helping individuals gain a greater sense of control over their health status.</p></sec><sec id="s5c"><title>Limitations and generalisability</title><p>This study was a preliminary study in a naturalistic setting and as such did not have a robust design. There was not a control group and the participants were not randomly assigned to groups, therefore the results should be treated with caution. To ascertain whether the changes in symptom and functional reports were due to the interventions, an RCT should be conducted. Also, there was a high drop-out rate from time-one to time-two and this rate differed across groups. The highest drop-out rate was in the psychology group; while we cannot be sure why this occurred, it is postulated that the retention was poor in the group as the individuals in the psychology programme had more activities to engage in and may have felt overburdened with the research questionnaires in addition to their sessions and homework (this would not be the case in the combined group as the therapeutic activities are phased-in as mentioned hereinbefore).</p><p>In this study, each individual was guided to an appropriate treatment within an initial screening with clinic staff; therefore the group was dependent on the nature of the individual's symptoms and their personal choice as the programmes on offer were privately funded. Notably, the groups did differ in general and physical fatigue with participants in the combined groups reporting greater fatigue than those in the psychology group which suggests that this group's general symptomatology was more severe. The combined group illustrated less change over time compared to the psychology and nutrition groups and it is feasible to infer that individuals with a greater number and degree of complaints are referred to the combined group within the clinic. Also, those in the combined group will not experience the intensity of each intervention as this has been demonstrated to result in non-compliance; therefore, changes in outcome measures in this group may not be noted at an interval of 3&#x02005;months. Further studies underway presently will investigate follow-ups at 6 and 12 months to identify whether the findings here are maintained over time and also whether those with a greater symptom severity benefit with a longer intervention. The results from this study will then inform plans for an RCT of the clinic's practices. As the participants were self-selected onto these programmes, the findings lack generalisability; future work should sample from the overall ME/CFS population and be randomly assigned to groups to make valid assumptions regarding the illness group as a whole.</p></sec></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="d34e118" content-type="local-data"><caption><title>Author's manuscript</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="bmjopen-2012-001079.draft_revisions.pdf"/></supplementary-material><supplementary-material id="d34e119" content-type="local-data"><caption><title>Reviewer comments</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="bmjopen-2012-001079.reviewer_comments.pdf"/></supplementary-material></sec></body><back><ack><p>We would like to thank Dr Tomas Ros for preparing the questionnaire spreadsheet, Niki Gratrix for helping in setting-up the study and Dr Andy McLellan and Val Duschinsky for proof-reading and editing.</p></ack><fn-group><fn><p><bold>Contributors:</bold> AH substantially contributed to the conception and design and acquisition of data, while MAA substantially contributed to the analysis and interpretation of data. Both authors made a substantial contribution to the drafting of the article and revisions for the critical review of important intellectual content. The final approval of the version to be published was also granted by both authors.</p></fn><fn><p><bold>Funding:</bold> No external funding was obtained for this research; the work was accomplished in-house at the clinic in question.</p></fn><fn><p><bold>Competing interests:</bold> AH is the founder and CEO of The Optimum Health Clinic and MAA is the Director of Research at the Optimum Health Clinic, where this study was conducted.</p></fn><fn><p><bold>Ethics approval:</bold> University of East London Ethics Committee.</p></fn><fn><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer-reviewed.</p></fn><fn><p><bold>Data sharing statement:</bold> Dataset available from the corresponding author at drarroll@theoptimumhealthclinic.com. Consent was not obtained for data sharing, but the presented data are anonymised and risk of identification is low.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukuda</surname><given-names>K</given-names></name><name><surname>Straus</surname><given-names>SE</given-names></name><name><surname>Hickie</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>The chronic fatigue syndrome: a comprehensive approach to its definition and study</article-title>. <source>Ann Intern Med</source>
<year>1994</year>;<volume>121</volume>:<fpage>953</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="pmid">7978722</pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jason</surname><given-names>LAE</given-names></name><name><surname>Fennell</surname><given-names>PAE</given-names></name><name><surname>Taylor</surname><given-names>RRE</given-names></name></person-group>
<source>Handbook of chronic fatigue syndrome</source>. <comment>Hoboken, NJ: John Wiley &#x00026; Sons, Inc</comment>, <year>2003</year></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>JR</given-names></name><name><surname>Couper</surname><given-names>J</given-names></name></person-group>
<article-title>Cognitive behaviour therapy for chronic fatigue syndrome in adults</article-title>. <source>Cochrane Database Syst Rev</source>
<year>1998</year>;<volume>4</volume>:<fpage>1</fpage>&#x02013;<lpage>38</lpage></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>JR</given-names></name><name><surname>Mitchell</surname><given-names>E</given-names></name><name><surname>Tidy</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Cognitive behaviour therapy for chronic fatigue syndrome in adults</article-title>. <source>Cochrane Database Syst Rev</source>
<year>2008</year>; <volume>3</volume><fpage>1</fpage>&#x02013;<lpage>98</lpage></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edmonds</surname><given-names>M</given-names></name><name><surname>McGuire</surname><given-names>H</given-names></name><name><surname>Price</surname><given-names>J</given-names></name></person-group>
<article-title>Exercise therapy for chronic fatigue syndrome</article-title>. <source>Cochrane Database Syst Rev</source>
<year>2004</year>;<volume>3</volume>:<fpage>1</fpage>&#x02013;<lpage>25</lpage></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>PD</given-names></name><name><surname>Goldsmith</surname><given-names>AL</given-names></name><name><surname>Johnson</surname><given-names>AL</given-names></name><etal/></person-group>
<article-title>Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial</article-title>. <source>Lancet</source>
<year>2011</year>;<volume>377</volume>:<fpage>823</fpage>&#x02013;<lpage>6</lpage><pub-id pub-id-type="pmid">21334061</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="book"><collab>National Institute for Health and Clinical Excellence</collab>
<source>Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy): diagnosis and management of CFS/ME in adults and children</source>. <publisher-loc>London</publisher-loc>: <publisher-name>NICE</publisher-name>; <year>2007</year></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wearden</surname><given-names>AJ</given-names></name><name><surname>Morriss</surname><given-names>RK</given-names></name><name><surname>Mullis</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Randomised, double-blind, placebo-controlled treatment trial of fluoxetine and graded exercise for chronic fatigue syndrome</article-title>. <source>Br J Psychiatry</source>
<year>1998</year>;<volume>172</volume>:<fpage>485</fpage>&#x02013;<lpage>90</lpage><pub-id pub-id-type="pmid">9828987</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vercoulen</surname><given-names>JH</given-names></name><name><surname>Swanink</surname><given-names>CM</given-names></name><name><surname>Zitman</surname><given-names>FG</given-names></name><etal/></person-group>
<article-title>Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome</article-title>. <source>Lancet</source>
<year>1996</year>;<volume>347</volume>:<fpage>858</fpage>&#x02013;<lpage>61</lpage><pub-id pub-id-type="pmid">8622391</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodnick</surname><given-names>PJ</given-names></name><name><surname>Jorge</surname><given-names>CM</given-names></name></person-group>
<article-title>Treatment of chronic fatigue syndrome with nefazodone</article-title>. <source>Am J Psychiatry</source>
<year>1999</year>;<volume>156</volume>:<fpage>797</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="pmid">10327922</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodnick</surname><given-names>PJ</given-names></name></person-group>
<article-title>Treatment of chronic fatigue syndrome with venlafaxine</article-title>. <source>Am J Psychiatry</source>
<year>1996</year>;<volume>153</volume>:<fpage>294</fpage><pub-id pub-id-type="pmid">8561218</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodnick</surname><given-names>PJ</given-names></name><name><surname>Sandoval</surname><given-names>R</given-names></name></person-group>
<article-title>Psychotropic treatment of chronic fatigue syndrome and related disorders</article-title>. <source>J Clin Psychiatry</source>
<year>1993</year>;<volume>54</volume>:<fpage>13</fpage>&#x02013;<lpage>20</lpage><pub-id pub-id-type="pmid">8428892</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodnick</surname><given-names>PJ</given-names></name><name><surname>Sandoval</surname><given-names>R</given-names></name><name><surname>Brickman</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome</article-title>. <source>Biol Psychiatry</source>
<year>1992</year>;<volume>32</volume>:<fpage>834</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="pmid">1450297</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hickie</surname><given-names>I</given-names></name></person-group>
<article-title>Nefazodone for patients with chronic fatigue syndrome</article-title>. <source>Aust N Z J Psychiatry</source>
<year>1999</year>;<volume>33</volume>:<fpage>278</fpage>&#x02013;<lpage>80</lpage><pub-id pub-id-type="pmid">10336228</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>P</given-names></name><name><surname>Schwartz</surname><given-names>S</given-names></name><name><surname>Furst</surname><given-names>G</given-names></name></person-group>
<article-title><italic>Medical Intervention and Management</italic>. In:</article-title><comment>Jason LA, Fennell PA, RR Taylor RR (eds). Handbook of Chronic Fatigue Syndrome. Hoboken, NJ: John Wiley &#x00026; Sons, Inc,. 2003. pp 441&#x02013;54.</comment></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Afari</surname><given-names>N</given-names></name><name><surname>Buchwald</surname><given-names>D</given-names></name></person-group>
<article-title>Chronic fatigue syndrome: a review</article-title>. <source>Am J Psychiatry</source>
<year>2003</year>;<volume>160</volume>:<fpage>221</fpage>&#x02013;<lpage>36</lpage><pub-id pub-id-type="pmid">12562565</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reid</surname><given-names>S</given-names></name><name><surname>Chalder</surname><given-names>T</given-names></name><name><surname>Cleare</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Extracts from &#x02018;Clinical Evidence&#x02019;: chronic fatigue syndrome</article-title>. <source>BMJ</source>
<year>2000</year>;<volume>320</volume>:<fpage>292</fpage>&#x02013;<lpage>6</lpage><pub-id pub-id-type="pmid">10650029</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Lange</surname><given-names>G</given-names></name><name><surname>Cook</surname><given-names>DB</given-names></name><name><surname>Natelson</surname><given-names>BH</given-names></name></person-group>
<article-title>Rehabilitation and treatment of fatigue. In: DeLuca J (ed). Fatigue as a window to the Brain. Cambridge, MA: The MIT Press</article-title>. <year>2005</year>
<comment>pp 301&#x02013;16</comment></mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>J</given-names></name><name><surname>Boorman</surname><given-names>J</given-names></name><name><surname>Cann</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome</article-title>. <source>Gut</source>
<year>2000</year>;<volume>47</volume>(<issue>Suppl II</issue>):<fpage>ii1</fpage>&#x02013;<lpage>19</lpage><pub-id pub-id-type="pmid">11053260</pub-id></mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>G</given-names></name><name><surname>McKendrick</surname><given-names>M</given-names></name><name><surname>Peet</surname><given-names>M</given-names></name></person-group>
<article-title>The role of essential fatty acids in chronic fatigue syndrome: a case-controlled study of red-cell membrane essential fatty acids (EFA) and a placebo-controlled treatment study with high dose of EFA</article-title>. <source>Acta Neurol Scand</source>
<year>1999</year>;<volume>99</volume>:<fpage>112</fpage>&#x02013;<lpage>16</lpage><pub-id pub-id-type="pmid">10071170</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaslow</surname><given-names>JE</given-names></name><name><surname>Rucker</surname><given-names>L</given-names></name><name><surname>Onishi</surname><given-names>R</given-names></name></person-group>
<article-title>Liver extract-folic acid-cyanocobalamin vs placebo for chronic fatigue syndrome</article-title>. <source>Arch Intern Med</source>
<year>1989</year>;<volume>149</volume>:<fpage>2501</fpage>&#x02013;<lpage>3</lpage><pub-id pub-id-type="pmid">2684076</pub-id></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kodama</surname><given-names>M</given-names></name><name><surname>Kodama</surname><given-names>T</given-names></name><name><surname>Murakami</surname><given-names>M</given-names></name></person-group>
<article-title>The value of the dehydroepiandrosterone-annexed vitamin C infusion treatment in the clinical control of chronic fatigue syndrome (CFS). II. Characterization of CFS patients with special reference to their response to a new vitamin C infusion treatment</article-title>. <source>In Vivo</source>
<year>1996</year>;<volume>10</volume>:<fpage>585</fpage>&#x02013;<lpage>96</lpage><pub-id pub-id-type="pmid">8986468</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langsjoen</surname><given-names>PH</given-names></name><name><surname>Folkers</surname><given-names>K</given-names></name></person-group>
<article-title>Isolated diastolic dysfunction of the myocardium and its response to CoQ10 treatment</article-title>. <source>Clin Investigator</source>
<year>1993</year>;<volume>71</volume>:<fpage>S140</fpage>&#x02013;<lpage>4</lpage></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>IM</given-names></name><name><surname>Campbell</surname><given-names>MJ</given-names></name><name><surname>Dowson</surname><given-names>D</given-names></name></person-group>
<article-title>Red blood cell magnesium and chronic fatigue syndrome</article-title>. <source>Lancet</source>
<year>1991</year>;<volume>337</volume>:<fpage>757</fpage>&#x02013;<lpage>60</lpage><pub-id pub-id-type="pmid">1672392</pub-id></mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bentler</surname><given-names>SE</given-names></name><name><surname>Hartz</surname><given-names>AJ</given-names></name><name><surname>Kuhn</surname><given-names>EM</given-names></name></person-group>
<article-title>Prospective observational study of treatments for unexplained chronic fatigue</article-title>. <source>J Clin Psychiatry</source>
<year>2005</year>;<volume>66</volume>: <fpage>632</fpage></mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>RWY</given-names></name><name><surname>Ogston</surname><given-names>SA</given-names></name><name><surname>Evans</surname><given-names>JR</given-names></name></person-group>
<article-title>Effects of vitamin and mineral supplementation on symptoms associated with chronic fatigue syndrome with coxsackie B antibodies</article-title>. <source>J Nutr Environ Med</source>
<year>2008</year>;<volume>4</volume>:<fpage>11</fpage>&#x02013;<lpage>23</lpage></mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiebe</surname><given-names>E</given-names></name></person-group>
<article-title>N of 1 trails. Managing patients with chronic fatigue syndrome: two case reports</article-title>. <source>Can Fam Physician</source>
<year>1996</year>;<volume>42</volume>:<fpage>2214</fpage>&#x02013;<lpage>17</lpage><pub-id pub-id-type="pmid">8939323</pub-id></mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brouwers</surname><given-names>FM</given-names></name><name><surname>Van Der Werf</surname><given-names>S</given-names></name><name><surname>Bleijenberg</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>The effect of a polynutrient supplement on fatigue and physical activity of patients with chronic fatigue syndrome: a double-blind randomized controlled trial</article-title>. <source>QJM</source>
<year>2002</year>;<volume>95</volume>:<fpage>677</fpage>&#x02013;<lpage>83</lpage><pub-id pub-id-type="pmid">12324640</pub-id></mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Afari</surname><given-names>N</given-names></name><name><surname>Eisenberg</surname><given-names>DM</given-names></name><name><surname>Herrell</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Use of alternative treatments by chronic fatigue syndrome discordant twins</article-title>. <source>Integr Med</source>
<year>2000</year>;<volume>2</volume>:<fpage>97</fpage>&#x02013;<lpage>103</lpage><pub-id pub-id-type="pmid">10882883</pub-id></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchwald</surname><given-names>D</given-names></name><name><surname>Garrity</surname><given-names>D</given-names></name></person-group>
<article-title>Comparison of patients with chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities</article-title>. <source>Arch Intern Med</source>
<year>1994</year>;<volume>154</volume>:<fpage>2049</fpage>&#x02013;<lpage>53</lpage><pub-id pub-id-type="pmid">8092909</pub-id></mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>NA</given-names></name><name><surname>Jason</surname><given-names>LA</given-names></name><name><surname>Boulton</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Alternative medical interventions used in the treatment and management of myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia</article-title>. <source>J Altern Complement Med</source>
<year>2010</year>;<volume>16</volume>:<fpage>235</fpage>&#x02013;<lpage>49</lpage><pub-id pub-id-type="pmid">20192908</pub-id></mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alraek</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>MS</given-names></name><name><surname>Choi</surname><given-names>TY</given-names></name><etal/></person-group>
<article-title>Complementary and alternative medicine for patients with chronic fatigue syndrome: a systematic review</article-title>. <source>BMC Complement Altern Med</source>
<year>2010</year>;<volume>11</volume>
<comment><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1472&#x02013;6882/11/87">http://www.biomedcentral.com/1472&#x02013;6882/11/87</ext-link> (accessed 20 Jan 2012).</comment></mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>A</given-names></name><name><surname>Arroll</surname><given-names>M</given-names></name></person-group>
<article-title>The application of integral medicine in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome</article-title>. <source>J Int Theory and Pract</source>
<year>2011</year>;<volume>6</volume>:<fpage>25</fpage>&#x02013;<lpage>40</lpage></mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>JE</given-names></name><name><surname>Sherbourne</surname><given-names>CD</given-names></name></person-group>
<article-title>The MOS 36-Item Short-Form Health Survey (SF-36)</article-title>. <source>Med Care</source>
<year>1992</year>;<volume>30</volume>:<fpage>473</fpage>&#x02013;<lpage>81</lpage><pub-id pub-id-type="pmid">1593914</pub-id></mixed-citation></ref><ref id="R35"><label>35</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>C</given-names></name><name><surname>Bayliss</surname><given-names>MS</given-names></name><name><surname>Ware</surname><given-names>JE</given-names></name></person-group>
<source>Health survey annotated bibliography</source>. <edition>2nd edn</edition> (<comment>1988&#x02013;1996</comment>). <publisher-loc>Boston, MA</publisher-loc>: <publisher-name>Health Assessment Lab, New England Medical Center</publisher-name>, <year>1997</year></mixed-citation></ref><ref id="R36"><label>36</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>JE</given-names></name><name><surname>Kosinski</surname><given-names>M</given-names></name><name><surname>Keller</surname><given-names>SK</given-names></name></person-group>
<source>SF-36 physical and mental health summary scales: a user's manual</source>. <publisher-loc>Boston, MA</publisher-loc>: <publisher-name>New England Medical Center, The Health Institute</publisher-name>, <year>1994</year></mixed-citation></ref><ref id="R37"><label>37</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>JE</given-names></name><name><surname>Snow</surname><given-names>KK</given-names></name><name><surname>Kosinski</surname><given-names>M</given-names></name><etal/></person-group>
<source>SF-36 health survey manual and interpretation guide</source>. <publisher-loc>Boston, MA</publisher-loc>: <publisher-name>New England Medical Center, The Health Institute</publisher-name>, <year>1993</year></mixed-citation></ref><ref id="R38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smets</surname><given-names>E-MA</given-names></name><name><surname>Garssen</surname><given-names>B</given-names></name><name><surname>Bonke</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue</article-title>. <source>J Psychosom Res</source>
<year>1995</year>;<volume>39</volume>:<fpage>315</fpage>&#x02013;<lpage>25</lpage><pub-id pub-id-type="pmid">7636775</pub-id></mixed-citation></ref><ref id="R39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>D</given-names></name><name><surname>Nisenbaum</surname><given-names>R</given-names></name><name><surname>Heim</surname><given-names>CJ</given-names></name><etal/></person-group>
<article-title>Psychometric properties of the CDC symptom inventory for assessment of chronic fatigue syndrome</article-title>. <source>Popul Health Metrics</source>
<year>2005</year>;<volume>3</volume>
<comment>doi:10.1186/1478-7954-3-8</comment></mixed-citation></ref><ref id="R40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chalder</surname><given-names>T</given-names></name><name><surname>Bereloitz</surname><given-names>G</given-names></name><name><surname>Pawlikowska</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Development of a fatigue scale</article-title>. <source>J Psychosom Res</source>
<year>1993</year>;<volume>37</volume>:<fpage>147</fpage>&#x02013;<lpage>53</lpage><pub-id pub-id-type="pmid">8463991</pub-id></mixed-citation></ref><ref id="R41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallston</surname><given-names>KA</given-names></name><name><surname>Wallston</surname><given-names>BS</given-names></name><name><surname>DeVellis</surname><given-names>R</given-names></name></person-group>
<article-title>Development of the Multidimensional Health Locus of Control (MHLC) Scales</article-title>. <source>Health Educ Monogr</source>
<year>1978</year>;<volume>6</volume>:<fpage>160</fpage>&#x02013;<lpage>70</lpage><pub-id pub-id-type="pmid">689890</pub-id></mixed-citation></ref><ref id="R42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallston</surname><given-names>KA</given-names></name><name><surname>Stein</surname><given-names>MJ</given-names></name><name><surname>Smith</surname><given-names>CA</given-names></name></person-group>
<article-title>Form C of the MHLC Scales: a condition-specific measure of locus of control</article-title>. <source>J Pers Asses</source>
<year>1994</year>;<volume>63</volume>:<fpage>534</fpage>&#x02013;<lpage>53</lpage></mixed-citation></ref><ref id="R43"><label>43</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wallston</surname><given-names>KA</given-names></name><name><surname>Wallston</surname><given-names>BS</given-names></name></person-group>
<article-title>Health locus of control scales</article-title>. In: <person-group person-group-type="editor"><name><surname>Lefcourt</surname><given-names>H</given-names></name></person-group>ed. <source>Advances and innovations in locus of control research</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Academic Press</publisher-name>, <year>1980</year></mixed-citation></ref><ref id="R44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levenson</surname><given-names>H</given-names></name></person-group>
<article-title>Multidimensional locus of control in psychiatric patients</article-title>. <source>J Consult Clin Psychol</source>
<year>1973</year>;<volume>41</volume>:<fpage>397</fpage>&#x02013;<lpage>404</lpage><pub-id pub-id-type="pmid">4803272</pub-id></mixed-citation></ref></ref-list></back></article>